_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502249547,7/11/2014 13:40:10,,1320736006,7/11/2014 13:39:58,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,tests and the BRONCHIAL HYPERREACTIVITY to methacholine inhalation,76-82-86-90-100-116-119-132,90-100-116-119-132-143-153,bronchial hyperreactivity to METHACHOLINE inhalation challenge were,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 13:41:31,,1320736407,7/11/2014 13:41:06,prodege,1,9525153,CAN,ON,Toronto,174.91.127.14,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,tests and the BRONCHIAL HYPERREACTIVITY to methacholine inhalation,76-82-86-90-100-116-119-132,90-100-119,bronchial hyperreactivity METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 13:45:45,,1320738011,7/11/2014 13:45:23,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY to methacholine inhalation,90-100-116-119-132,119-132,METHACHOLINE inhalation,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 13:49:09,,1320739359,7/11/2014 13:48:44,instagc,1,13763729,USA,"","",75.182.89.225,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119,METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 13:56:25,,1320741648,7/11/2014 13:56:05,clixsense,1,26283440,GBR,C7,Coventry,86.20.175.18,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119,METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 13:59:29,,1320742811,7/11/2014 13:59:10,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119,METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 14:03:39,,1320744560,7/11/2014 14:02:52,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119,METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 14:04:08,,1320744792,7/11/2014 14:03:56,instagc,1,23149109,USA,NC,Cary,24.206.38.18,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119-132,METHACHOLINE inhalation,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 14:05:39,,1320745473,7/11/2014 14:05:23,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,119,METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249547,7/11/2014 14:05:50,,1320745526,7/11/2014 14:05:36,prodege,1,1889141,USA,NC,Kinston,75.110.92.24,90,119,,,115,131,BRONCHIAL HYPERREACTIVITY,METHACHOLINE,BRONCHIAL HYPERREACTIVITY,90-100,90-100-116-119,bronchial hyperreactivity to METHACHOLINE,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study.",90 100,119,90,119,115,131,1,RO-may_diagnose,906914,"The duration and severity of BA, the presence of allergy determined by skin tests and the bronchial hyperreactivity to methacholine inhalation challenge were observed on the first day of study",bronchial hyperreactivity,methacholine
502249548,7/11/2014 13:28:55,,1320732371,7/11/2014 13:28:34,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:33:51,,1320734036,7/11/2014 13:33:33,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,42-50-56-61,classic RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:41:48,,1320736538,7/11/2014 13:41:43,clixsense,1,9343409,NLD,"","",194.120.71.114,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,renal cell carcinoma: HAEMATURIA and flank pain.,50-56-61-72-83-87-93,35-38-42-50-56-61-72-83-87,in the classic RENAL CELL CARCINOMA: haematuria and flank,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:45:21,,1320737829,7/11/2014 13:45:07,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,renal cell carcinoma: HAEMATURIA,50-56-61-72,50-56-61-72,RENAL CELL CARCINOMA: haematuria,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:48:16,,1320738993,7/11/2014 13:47:41,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,renal cell carcinoma: HAEMATURIA and flank pain.,50-56-61-72-83-87-93,35-38-42-50-56-61-72-83-87,in the classic RENAL CELL CARCINOMA: haematuria and flank,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:52:32,,1320740426,7/11/2014 13:52:17,instagc,1.0,13763729,USA,"","",75.182.89.225,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:57:22,,1320741988,7/11/2014 13:57:04,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 13:58:54,,1320742569,7/11/2014 13:58:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 14:03:37,,1320744552,7/11/2014 14:03:23,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249548,7/11/2014 14:07:28,,1320746231,7/11/2014 14:07:09,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,72,50,,,82,70,HAEMATURIA,RENAL CELL CARCINOMA,HAEMATURIA,72,50-56-61,RENAL CELL CARCINOMA:,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain.,72,50 56 61,72,50,82,70,1,RO-disease_may_have_finding,902711,The major symptoms are the same as in the classic renal cell carcinoma: haematuria and flank pain,haematuria,renal cell carcinoma
502249549,7/11/2014 13:32:57,,1320733751,7/11/2014 13:32:40,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,439,419,,,443,431,SKIN,PERSPIRATION,SKIN.,439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:40:32,,1320736129,7/11/2014 13:40:24,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,439,419,,,443,431,SKIN,PERSPIRATION,perspiration on the SKIN.,419-432-435-439,403-408-416-419-432-435-439,from nitrite in PERSPIRATION on the skin.,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:42:23,,1320736743,7/11/2014 13:42:10,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,439,419,,,443,431,SKIN,PERSPIRATION,SKIN.,439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:42:27,,1320736772,7/11/2014 13:42:08,prodege,1,27934334,GBR,F6,Romford,86.162.39.238,439,419,,,443,431,SKIN,PERSPIRATION,SKIN.,439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:43:31,,1320737228,7/11/2014 13:42:36,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,439,419,,,443,431,SKIN,PERSPIRATION,circulating nitrite vasodilation in ischemic tissue perspiration on the SKIN.,208-220-243-256-259-419-432-435-439-268,403-408-416-419-432-435-439,from nitrite in PERSPIRATION on the skin.,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:43:46,,1320737296,7/11/2014 13:43:38,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,439,419,,,443,431,SKIN,PERSPIRATION,SKIN.,439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 13:47:06,,1320738542,7/11/2014 13:46:35,clixsense,1.0,9343409,NLD,"","",194.120.71.114,439,419,,,443,431,SKIN,PERSPIRATION,guanylyl cyclase vasodilation perspiration on the SKIN.,151-160-419-432-435-439-243,151-160-403-408-416-419-432-435-439-243,guanylyl cyclase vasodilation from nitrite in PERSPIRATION on the skin.,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 14:01:44,,1320743732,7/11/2014 14:01:33,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,439,419,,,443,431,SKIN,PERSPIRATION,SKIN.,439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 14:08:45,,1320746815,7/11/2014 14:08:35,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,439,419,,,443,431,SKIN,PERSPIRATION,perspiration on the SKIN.,419-432-439-435,419-432-435-439,PERSPIRATION on the skin.,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249549,7/11/2014 14:09:10,,1320747000,7/11/2014 14:08:45,vivatic,1,25451531,GBR,"","",83.67.28.193,439,419,,,443,431,SKIN,PERSPIRATION,the SKIN.,435-439,419,PERSPIRATION,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin.",439,419,439,419,443,431,1,RO-has_finding_site,905376,"It might take at least 12 days, when the pH of nitrite solution is lowered, for the concentration of NO to reach a level sufficiently high to activate guanylyl cyclase and so it seems unlikely that naturally circulating nitrite is involved in vasodilation in ischemic tissue through its conversion into NO. It is more realistic to consider that NO is produced at biologically significant concentrations from nitrite in perspiration on the skin",skin,perspiration
502249550,7/11/2014 13:27:37,,1320731993,7/11/2014 13:27:10,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,39,0,,,45,11,ANGINA,ANTIANGINAL,"ANGINA diares,",39-46,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 13:54:35,,1320741080,7/11/2014 13:54:19,instagc,1.0,13763729,USA,"","",75.182.89.225,39,0,,,45,11,ANGINA,ANTIANGINAL,ANGINA,39,0,ANTIANGINAL,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 13:55:11,,1320741269,7/11/2014 13:54:48,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,39,0,,,45,11,ANGINA,ANTIANGINAL,ANGINA,39,0,ANTIANGINAL,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 13:59:44,,1320742901,7/11/2014 13:59:20,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,39,0,,,45,11,ANGINA,ANTIANGINAL,"ANGINA diares,",39-46,0,ANTIANGINAL,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:08:35,,1320746734,7/11/2014 14:08:23,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,39,0,,,45,11,ANGINA,ANTIANGINAL,"ANGINA diares,",39-46,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:09:38,,1320747159,7/11/2014 14:08:52,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,39,0,,,45,11,ANGINA,ANTIANGINAL,ANGINA,39,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:09:41,,1320747178,7/11/2014 14:09:28,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,39,0,,,45,11,ANGINA,ANTIANGINAL,"ANGINA diares,",39-46,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:10:56,,1320747655,7/11/2014 14:10:27,prodege,1,1852770,USA,TX,Abilene,76.198.102.54,39,0,,,45,11,ANGINA,ANTIANGINAL,ANGINA,39,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:11:19,,1320747816,7/11/2014 14:11:05,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,39,0,,,45,11,ANGINA,ANTIANGINAL,"ANGINA diares,",39-46,0-12,ANTIANGINAL efficacy,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249550,7/11/2014 14:12:49,,1320748415,7/11/2014 14:12:15,instagc,1,21777979,USA,GA,Warner Robins,174.78.194.199,39,0,,,45,11,ANGINA,ANTIANGINAL,"Antianginal efficacy was assessed with ANGINA diares, investigators, and",0-21-25-34-39-46-54-69-12,0-12-21-25-39-46,"ANTIANGINAL efficacy was assessed angina diares,","Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy.",39,0,39,0,45,11,1,RO-may_prevent,907376,"Antianginal efficacy was assessed with angina diares, investigators, and patients global evaluations and with treadmill exercise test during placebo run-in-period and after 8 weeks of the therapy",angina,Antianginal
502249551,7/11/2014 13:36:14,,1320734780,7/11/2014 13:35:42,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"OVARIES,",212,153-161,OVARIAN ADENOCARCINOMA,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:38:40,,1320735518,7/11/2014 13:38:11,clixsense,1.0,9343409,NLD,"","",194.120.71.114,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"autologous membrane bound antibodies ovarian adenocarcinoma with normal human OVARIES, non ovarian normal immunofluorescence assay.",4-15-24-30-153-161-194-199-206-212-221-225-233-308-327,4-15-24-30-134-144-147-153-161-176-180-184-308-327,autologous membrane bound antibodies specimens of human OVARIAN ADENOCARCINOMA but did not immunofluorescence assay.,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:39:34,,1320735789,7/11/2014 13:39:31,prodege,1,18960400,GBR,A2,Edgware,31.54.207.221,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"with normal human OVARIES, non ovarian normal",194-199-206-212-221-225-233,134-144-147-153-161-176-180-184,specimens of human OVARIAN ADENOCARCINOMA but did not,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:43:56,,1320737338,7/11/2014 13:43:43,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"OVARIES,",212,153-161,OVARIAN ADENOCARCINOMA,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:44:04,,1320737398,7/11/2014 13:43:50,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"with normal human OVARIES, non ovarian normal",194-199-206-212-221-225-233,134-144-147-153-161-176-180-184-188,specimens of human OVARIAN ADENOCARCINOMA but did not react,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:50:40,,1320739815,7/11/2014 13:49:36,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"autologous membrane bound antibodies cell surface antigens four human ovarian cell human ovarian adenocarcinoma OVARIES, non ovarian normal neoplastic tissues, non ovarian human cell lines indirect immunofluorescence assay.",4-15-24-30-61-66-74-86-91-97-105-147-153-161-212-221-225-233-244-255-267-271-279-290-299-308-327-285,4-15-24-30-61-66-74-86-91-97-105-144-147-153-161-212-221-224-225-233-244-255-267-271-279-285-290-299-308-327,"autologous membrane bound antibodies cell surface antigens four human ovarian cell of human OVARIAN ADENOCARCINOMA ovaries, non - ovarian normal neoplastic tissues, non ovarian human cell lines indirect immunofluorescence assay.","The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 13:55:08,,1320741250,7/11/2014 13:54:50,instagc,1.0,13763729,USA,"","",75.182.89.225,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"OVARIES,",212,153-161,OVARIAN ADENOCARCINOMA,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 14:02:48,,1320744223,7/11/2014 14:02:10,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"ovarian adenocarcinoma OVARIES,",153-212-161,153-161-206-212,"OVARIAN ADENOCARCINOMA human ovaries,","The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 14:05:02,,1320745151,7/11/2014 14:04:42,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"OVARIES,",212,153-161,OVARIAN ADENOCARCINOMA,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249551,7/11/2014 14:08:50,,1320746854,7/11/2014 14:08:03,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,212,153,,,219,175,OVARIES,OVARIAN ADENOCARCINOMA,"OVARIES,",212,153-161,OVARIAN ADENOCARCINOMA,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay.",212,153 161,212,153,219,175,1,RO-disease_has_primary_anatomic_site,902097,"The autologous membrane-bound antibodies strongly recognized cell-surface antigens on four human ovarian cell lines and four surgical specimens of human ovarian adenocarcinoma but did not react with normal human ovaries, non-ovarian normal and neoplastic tissues, or non-ovarian human cell lines by indirect immunofluorescence assay",ovaries,ovarian adenocarcinoma
502249552,7/11/2014 13:26:34,,1320731630,7/11/2014 13:26:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:44:30,,1320737547,7/11/2014 13:44:13,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS of the knee,186-201-204-208,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:48:08,,1320738959,7/11/2014 13:47:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:49:35,,1320739504,7/11/2014 13:48:01,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,"intraarticular hyaluronan osteoarthritis analgesic efficacy naproxen sodium OSTEOARTHRITIS knee Lancet Comparison lumiracoxib naproxen ibuprofen Therapeutic Arthritis Research Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Pathogenesis osteoarthritis Acupuncture osteoarthritis knee: gastrointestinal etoricoxib diclofenac osteoarthritis rheumatoid arthritis Multinational Etoricoxib Diclofenac Arthritis.",3-18-32-78-88-136-186-208-214-222-236-253-266-283-295-305-318-335-341-347-357-372-382-393-404-411-450-466-495-517-563-590-605-633-652-663-680-694-709-720-145,3-18-32-54-78-88-136-145-156-186-208-214-222-236-253-266-283-295-305-318-335-341-347-357-372-393-404-411-450-466-495-557-563-580-605-633-652-663-680-694-709-720-590,"intraarticular hyaluronan osteoarthritis knee analgesic efficacy naproxen sodium ibuprofen osteoarthritis knee Lancet Comparison lumiracoxib NAPROXEN ibuprofen Therapeutic Arthritis Research Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: controlled trial Pathogenesis osteoarthritis Acupuncture osteoarthritis upper gastrointestinal safety etoricoxib diclofenac osteoarthritis rheumatoid arthritis Multinational Etoricoxib Diclofenac Arthritis.","of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:50:47,,1320739870,7/11/2014 13:50:13,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,the treatment of OSTEOARTHRITIS of the knee,169-173-183-186-201-204-208,233-236-248-253-262-266-276-279-283,of lumiracoxib with NAPROXEN and ibuprofen in the Therapeutic,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:53:32,,1320740790,7/11/2014 13:53:13,instagc,1.0,13763729,USA,"","",75.182.89.225,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 13:56:04,,1320741518,7/11/2014 13:55:45,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 14:05:09,,1320745243,7/11/2014 14:04:46,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,236-248-253,lumiracoxib with NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 14:07:47,,1320746341,7/11/2014 14:07:26,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,236-248-253-262-266,lumiracoxib with NAPROXEN and ibuprofen,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249552,7/11/2014 14:08:49,,1320746842,7/11/2014 14:08:20,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,186,253,,,200,261,OSTEOARTHRITIS,NAPROXEN,OSTEOARTHRITIS,186,253,NAPROXEN,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis.",186,253,186,253,200,261,1,RO-may_treat,907732,"of intraarticular hyaluronan in osteoarthritis of the knee  Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and ibuprofen in the treatment of osteoarthritis of the knee  Lancet  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial  Pathogenesis and management of pain in osteoarthritis  Acupuncture in patients with osteoarthritis of the knee: a randomised trial  Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis",osteoarthritis,naproxen
502249553,7/11/2014 13:28:14,,1320732200,7/11/2014 13:27:53,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 13:34:45,,1320734367,7/11/2014 13:34:24,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 13:37:20,,1320735077,7/11/2014 13:37:03,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,canine ATOPIC DERMATITIS,70-77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 13:42:05,,1320736617,7/11/2014 13:41:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119-126,ATOPIC dogs,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 13:47:30,,1320738706,7/11/2014 13:47:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 13:50:48,,1320739874,7/11/2014 13:50:31,instagc,1.0,13763729,USA,"","",75.182.89.225,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 14:03:07,,1320744343,7/11/2014 14:02:50,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 14:07:07,,1320746059,7/11/2014 14:06:48,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 14:07:37,,1320746280,7/11/2014 14:06:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,ATOPIC DERMATITIS,77-84,119,ATOPIC,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249553,7/11/2014 14:08:50,,1320746845,7/11/2014 14:08:21,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,77,119,,,94,125,ATOPIC DERMATITIS,ATOPIC,canine ATOPIC DERMATITIS,77-84-70,119-126,ATOPIC dogs,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen.,77 84,119,77,119,94,125,-1,RO-cause_of,900177,Sensitization to allergens of Japanese cedar pollen is known to cause canine atopic dermatitis as approximately 10% of atopic dogs in Japan were positive to the pollen allergen,atopic dermatitis,atopic
502249554,7/11/2014 13:35:42,,1320734624,7/11/2014 13:35:19,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,86,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:37:47,,1320735223,7/11/2014 13:37:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE concentration,86-95,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:40:23,,1320736078,7/11/2014 13:40:11,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,"adjustment to the FLUORIDE concentration in drinking water,",68-79-82-86-95-109-112-121,121-128-132-137-144-154-163-170-185,"water, (2) that DENTAL FLUOROSIS develops during the stage","It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:40:47,,1320736226,7/11/2014 13:39:34,clixsense,1,18408026,USA,WA,Tacoma,131.191.72.163,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,"FLUORIDE dental fluorosis maturation stage dental fluorosis enamel secretion, Dean's index dental fluorosis",86-137-144-174-185-242-249-345-352-376-383-444-451,137-144-242-249-376-383-444-451,DENTAL FLUOROSIS dental fluorosis Dean's index dental fluorosis,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:45:48,,1320738030,7/11/2014 13:44:50,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,"FLUORIDE dental fluorosis enamel development, dental fluorosis enamel secretion, Dean's index dental fluorosis fluoride",86-137-144-194-201-242-249-345-352-376-444-451-489-383,86-128-132-137-144-194-201-242-249-345-352-376-383-444-451-489,"fluoride (2) that DENTAL FLUOROSIS enamel development, dental fluorosis enamel secretion, Dean's index dental fluorosis fluoride","It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:48:47,,1320739232,7/11/2014 13:48:34,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,86,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 13:49:15,,1320739383,7/11/2014 13:48:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE concentration in drinking,86-95-109-112,137-144-174-185-201-194,"DENTAL FLUOROSIS maturation stage enamel development,","It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 14:00:47,,1320743358,7/11/2014 14:00:25,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,86,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 14:00:50,,1320743377,7/11/2014 14:00:24,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE concentration,86-95,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249554,7/11/2014 14:02:01,,1320743838,7/11/2014 14:01:42,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,86,137,,,94,153,FLUORIDE,DENTAL FLUOROSIS,FLUORIDE,86,137-144,DENTAL FLUOROSIS,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water.",86,137 144,86,137,94,153,-1,RO-has_causative_agent,903790,"It was concluded (1) that CFI values were reduced following a minor adjustment to the fluoride concentration in drinking water, (2) that dental fluorosis develops during the maturation stage of enamel development, (3) that the development of dental fluorosis may occur over a period of 16 to 24 months, commencing from 12 to 32 months following enamel secretion, and (4) that Dean's index is a suitable instrument for monitoring the effects on dental fluorosis of minor adjustments to the fluoride concentration in drinking water",fluoride,dental fluorosis
502249555,7/11/2014 13:34:30,,1320734274,7/11/2014 13:34:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,188-196-207,PROTein derivative test.,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 13:39:03,,1320735634,7/11/2014 13:38:57,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,the incidence of MYCOBACTERIUM TUBERCULOSIS INFECTION among nursing students Esp����渇�膩�����鐃緒申鐃順�o,33-37-47-50-64-77-87-93-101-139,136-139-162-188-196-207-169,"of Esp����渇�膩�����鐃緒申鐃順�o SanTO, USING PROTein derivative test.","This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 13:41:43,,1320736512,7/11/2014 13:41:20,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,the incidence of MYCOBACTERIUM TUBERCULOSIS INFECTION among nursing students,33-37-47-50-64-77-87-93-101,136-139-162-188-196-207,"of Esp����渇�膩�����鐃緒申鐃順�o SanTO, PROTein derivative test.","This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 13:42:13,,1320736658,7/11/2014 13:41:49,clixsense,1.0,9343409,NLD,"","",194.120.71.114,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,the incidence of MYCOBACTERIUM TUBERCULOSIS INFECTION among nursing students purified protein derivative,33-37-47-50-64-77-87-93-101-179-188-196,50-64-136-139-162-188-196-207-77,"Mycobacterium tuberculosis infection of Esp����渇�膩�����鐃緒申鐃順�o SanTO, PROTein derivative test.","This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 13:51:09,,1320739969,7/11/2014 13:50:40,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION purified protein derivative test.,50-64-77-179-188-196-207,50-64-77-188-196-207-179,Mycobacterium tuberculosis infection PURIFIED PROTein derivative test.,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 13:53:12,,1320740668,7/11/2014 13:52:51,instagc,1.0,13763729,USA,"","",75.182.89.225,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,179-188-196,PURIFIED PROTein derivative,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 14:01:46,,1320743746,7/11/2014 14:01:17,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,188-196-207,PROTein derivative test.,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 14:02:08,,1320743878,7/11/2014 14:01:45,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,136-139-162-188-196-207,"of Esp����渇�膩�����鐃緒申鐃順�o SanTO, PROTein derivative test.","This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 14:04:27,,1320744907,7/11/2014 14:04:10,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,188-196-207,PROTein derivative test.,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249555,7/11/2014 14:04:41,,1320745014,7/11/2014 14:04:14,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,50,165,,,86,192,MYCOBACTERIUM TUBERCULOSIS INFECTION,PURIFIED PROTEIN DERIVATIVE,MYCOBACTERIUM TUBERCULOSIS INFECTION,50-64-77,188-196-179,PURIFIED PROTein derivative,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test.",50 64 77,,50,165,86,192,1,RO-may_diagnose,906748,"This prospective study evaluated the incidence of Mycobacterium tuberculosis infection among nursing students at the Federal University of Esp����渇�膩�����鐃緒申鐃順�o Santo, using the purified protein derivative test",Mycobacterium tuberculosis infection,purified protein derivative
502249556,7/11/2014 13:30:56,,1320733101,7/11/2014 13:30:36,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:38:27,,1320735449,7/11/2014 13:38:04,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,new strain of HANTAVIRUS.,64-68-75-78,0-11-21-36-39,HANTAVIRUS PULMONARY SYNDROME is a,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:39:53,,1320735916,7/11/2014 13:39:50,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,new strain of HANTAVIRUS.,64-68-75-78,0-11-21-36-39,HANTAVIRUS PULMONARY SYNDROME is a,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:41:07,,1320736317,7/11/2014 13:40:55,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:41:18,,1320736361,7/11/2014 13:41:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:44:05,,1320737403,7/11/2014 13:43:57,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:46:24,,1320738249,7/11/2014 13:46:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:47:36,,1320738752,7/11/2014 13:47:23,clixsense,1.0,9343409,NLD,"","",194.120.71.114,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,new strain of HANTAVIRUS.,64-68-75-78,0-11-21-36-39,HANTAVIRUS PULMONARY SYNDROME is a,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 13:53:37,,1320740818,7/11/2014 13:53:20,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21,HANTAVIRUS PULMONARY SYNDROME,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249556,7/11/2014 14:03:15,,1320744381,7/11/2014 14:03:03,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,78,0,,,88,29,HANTAVIRUS,HANTAVIRUS PULMONARY SYNDROME,HANTAVIRUS.,78,0-11-21-30,HANTAVIRUS PULMONARY SYNDROME (HPS),Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus.,78,0 11 21,78,0,88,29,1,RO-has_causative_agent,903801,Hantavirus pulmonary syndrome (HPS) is a viral infection from a new strain of Hantavirus,Hantavirus,Hantavirus pulmonary syndrome
502249557,7/11/2014 13:26:00,,1320731397,7/11/2014 13:25:44,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54-64,PAPILLARY THYROID CARCINOMA (PTC),Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:40:24,,1320736087,7/11/2014 13:40:16,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54-64,PAPILLARY THYROID CARCINOMA (PTC),Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:40:28,,1320736092,7/11/2014 13:40:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54,PAPILLARY THYROID CARCINOMA,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:40:29,,1320736116,7/11/2014 13:40:25,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,and presence of PSAMMOMA BODIES.,102-106-115-118-127,19-28-33-36-46-54-70-78,peculiar type of PAPILLARY THYROID CARCINOMA because of,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:43:50,,1320737316,7/11/2014 13:43:22,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,and presence of PSAMMOMA BODIES.,102-106-115-118-127,19-28-33-36-46-54-70-78-93,peculiar type of PAPILLARY THYROID CARCINOMA because of features,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:48:21,,1320739055,7/11/2014 13:48:08,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,and presence of PSAMMOMA BODIES.,102-106-115-118-127,19-28-33-36-46-54-70-78-106-115-118-127,peculiar type of PAPILLARY THYROID CARCINOMA because of presence of psammoma bodies.,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:51:55,,1320740216,7/11/2014 13:51:22,instagc,1.0,13763729,USA,"","",75.182.89.225,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54,PAPILLARY THYROID CARCINOMA,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 13:55:23,,1320741338,7/11/2014 13:54:58,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54-64,PAPILLARY THYROID CARCINOMA (PTC),Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 14:02:48,,1320744221,7/11/2014 14:02:35,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,PSAMMOMA BODIES.,118-127,36-46-54,PAPILLARY THYROID CARCINOMA,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249557,7/11/2014 14:05:22,,1320745314,7/11/2014 14:05:06,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,118,36,,,133,63,PSAMMOMA BODIES,PAPILLARY THYROID CARCINOMA,(PTC) PSAMMOMA BODIES.,118-127-64,36-46-54-78-64,PAPILLARY THYROID CARCINOMA (PTC) of,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies.,118 127,36 46 54,118,36,133,63,-1,RO-disease_may_have_finding,902823,Some consider it a peculiar type of papillary thyroid carcinoma (PTC) because of its nuclear features and presence of psammoma bodies,psammoma bodies,papillary thyroid carcinoma
502249558,7/11/2014 13:32:21,,1320733516,7/11/2014 13:32:01,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS subsets:,69-75,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:33:00,,1320733764,7/11/2014 13:32:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS,69,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:41:08,,1320736332,7/11/2014 13:40:52,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS,69,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:41:49,,1320736539,7/11/2014 13:41:44,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,the following distinctive LUPUS subsets: neonatal lupus,43-47-57-69-75-84-93,0-6-20-23-33,LUPUS ERYTHEMATOSUS in childhood comprises,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:42:52,,1320736961,7/11/2014 13:42:40,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS,69,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:43:20,,1320737126,7/11/2014 13:42:31,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,"LUPUS subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes subacute cutaneous lupus lesions, lupus panniculitis.",69-75-84-93-99-114-123-129-144-152-158-173-182-192-198-213-224-235-250-259-269-275-288-294,0-6-69-75-84-93-99-114-123-129-152-158-173-182-192-198-213-224-235-250-259-269-275-288-294-57,"LUPUS ERYTHEMATOSUS distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes subacute cutaneous lupus lesions, lupus panniculitis.","Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:47:40,,1320738777,7/11/2014 13:47:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,"the following distinctive LUPUS subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, lupus panniculitis.",43-47-57-69-75-84-93-99-114-123-129-144-152-158-173-182-192-198-213-224-235-245-250-259-269-275-288-294,0-6-20-23-33,LUPUS ERYTHEMATOSUS in childhood comprises,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:50:30,,1320739760,7/11/2014 13:50:16,instagc,1.0,13763729,USA,"","",75.182.89.225,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS,69,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:54:17,,1320741001,7/11/2014 13:53:58,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS neonatal lupus,69-84-93,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249558,7/11/2014 13:59:09,,1320742675,7/11/2014 13:58:55,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,69,0,,,74,19,LUPUS,LUPUS ERYTHEMATOSUS,LUPUS,69,0-6,LUPUS ERYTHEMATOSUS,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis.",69,0 6,69,0,74,19,-1,RO-cause_of,900305,"Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus, systemic lupus erythematosus, discoid lupus erythematosus, subacute cutaneous lupus erythematosus, complement deficiency syndromes with subacute cutaneous lupus lesions, and lupus panniculitis",lupus,Lupus erythematosus
502249559,7/11/2014 13:27:14,,1320731858,7/11/2014 13:26:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,LYMPH NODE sonography,97-103-108,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:32:58,,1320733750,7/11/2014 13:32:40,clixsense,1.0,9343409,NLD,"","",194.120.71.114,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,lymph node palpation versus high resolution LYMPH NODE sonography for the lymph node metastases malignant melanoma.,53-59-64-74-81-86-97-103-108-119-123-140-146-151-179-189,53-59-64-86-103-108-123-127-137-140-146-151-162-165-174-97,lymph node palpation resolution lymph node sonography the detection of LYMPH NODE METASTASES in patients with,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:38:56,,1320735593,7/11/2014 13:38:42,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,versus high resolution LYMPH NODE sonography for the patients malignant,74-81-86-97-103-108-119-123-165-179,53-123-127-137-140-146-151-162-165-174-64,lymph palpation the detection of LYMPH NODE METASTASES in patients with,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:39:37,,1320735805,7/11/2014 13:39:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,high resolution LYMPH NODE sonography,81-86-97-103-108,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:41:49,,1320736537,7/11/2014 13:41:28,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,LYMPH NODE,97-103,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:42:10,,1320736652,7/11/2014 13:41:57,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,versus high resolution LYMPH NODE sonography for the,74-81-86-97-103-108-119-123,140-146-151-179-189,LYMPH NODE METASTASES malignant melanoma.,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:44:13,,1320737448,7/11/2014 13:44:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,high resolution LYMPH NODE sonography,81-86-97-103-108,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:45:43,,1320737995,7/11/2014 13:45:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,LYMPH NODE,97-103,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:46:19,,1320738238,7/11/2014 13:45:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,LYMPH NODE sonography for the detection of lymph node metastases,97-103-108-119-123-127-137-140-146-151,123-127-137-140-146-151-162-165-174-179-189,the detection of LYMPH NODE METASTASES in patients with malignant melanoma.,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249559,7/11/2014 13:48:25,,1320739084,7/11/2014 13:48:06,instagc,1.0,13763729,USA,"","",75.182.89.225,97,140,,,107,161,LYMPH NODE,LYMPH NODE METASTASES,LYMPH NODE,97-103,140-146-151,LYMPH NODE METASTASES,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma.,97 103,140 146 151,97,140,107,161,1,RO-has_finding_site,905419,The aim of this study was to examine the efficacy of lymph node palpation versus high resolution lymph node sonography for the detection of lymph node metastases in patients with malignant melanoma,lymph node,lymph node metastases
502249560,7/11/2014 13:39:00,,1320735604,7/11/2014 13:38:33,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:40:10,,1320736007,7/11/2014 13:40:03,tremorgames,1,17552229,GBR,A2,Edgware,31.54.207.221,102,26,,,107,40,JOINT,JOINT EFFUSION,"and around the JOINT, is related to",87-91-98-102-109-112-120,7-12-21-26-32-42-46-56,"been reported that JOINT EFFUSION, the excessive accumulation","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:44:26,,1320737523,7/11/2014 13:44:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:48:59,,1320739281,7/11/2014 13:48:17,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,102,26,,,107,40,JOINT,JOINT EFFUSION,"and around the JOINT, is related to temporomandibular",87-91-98-102-109-112-120-123,7-12-21-26-32-42-46-56,"been reported that JOINT EFFUSION, the excessive accumulation","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:49:25,,1320739423,7/11/2014 13:49:10,instagc,1.0,13763729,USA,"","",75.182.89.225,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:55:07,,1320741239,7/11/2014 13:54:41,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 13:58:02,,1320742194,7/11/2014 13:57:40,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 14:05:49,,1320745515,7/11/2014 14:05:38,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,102,26,,,107,40,JOINT,JOINT EFFUSION,"JOINT,",102,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 14:07:26,,1320746220,7/11/2014 14:07:07,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,102,26,,,107,40,JOINT,JOINT EFFUSION,"joint effusion, JOINT,",26-102-32,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249560,7/11/2014 14:10:06,,1320747353,7/11/2014 14:09:21,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,102,26,,,107,40,JOINT,JOINT EFFUSION,"the excessive accumulation of joint fluid in and around the JOINT,",42-46-56-69-72-78-84-87-91-102-98,26-32,"JOINT EFFUSION,","It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement.",102,26 32,102,26,107,40,1,RO-has_finding_site,905403,"It has been reported that joint effusion, the excessive accumulation of joint fluid in and around the joint, is related to temporomandibular joint (TMJ) disorders such as pain and disk displacement",joint,joint effusion
502249561,7/11/2014 13:37:06,,1320735013,7/11/2014 13:36:43,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:38:54,,1320735572,7/11/2014 13:38:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110-117,CARIES development,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:40:19,,1320736053,7/11/2014 13:40:14,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,85,110,,,93,116,BACTERIA,CARIES,supplemented with probiotic BACTERIA and fluoride on,57-70-75-85-94-98-107,94-98-107-110-117-129-133,and fluoride on CARIES development and general,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:42:43,,1320736856,7/11/2014 13:42:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:43:21,,1320737137,7/11/2014 13:43:05,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:47:21,,1320738685,7/11/2014 13:47:07,clixsense,1.0,9343409,NLD,"","",194.120.71.114,85,110,,,93,116,BACTERIA,CARIES,supplemented with probiotic BACTERIA and fluoride on,57-70-75-85-94-98-107,94-98-107-110-117-129-133,and fluoride on CARIES development and general,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:48:07,,1320738951,7/11/2014 13:47:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,85,110,,,93,116,BACTERIA,CARIES,supplemented with probiotic BACTERIA and fluoride on,57-70-75-85-94-98-107,110-117-129-133-141-148-151-161,CARIES development and general health in preschool children.,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 13:56:45,,1320741794,7/11/2014 13:56:26,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,85,110,,,93,116,BACTERIA,CARIES,BACTERIA,85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 14:01:58,,1320743812,7/11/2014 14:01:45,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249561,7/11/2014 14:07:24,,1320746196,7/11/2014 14:07:08,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,85,110,,,93,116,BACTERIA,CARIES,probiotic BACTERIA,75-85,110,CARIES,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children.,85,110,85,110,93,116,-1,RO-has_causative_agent,903916,The aim of this study was to evaluate the effect of milk supplemented with probiotic bacteria and fluoride on caries development and general health in preschool children,bacteria,caries
502249562,7/11/2014 13:26:12,,1320731520,7/11/2014 13:26:01,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,106,44,,,115,52,HEADACHES,MIGRAINE,tension type HEADACHES.,93-101-106,44-53,MIGRAINE headaches,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:31:52,,1320733346,7/11/2014 13:31:25,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,106,44,,,115,52,HEADACHES,MIGRAINE,tension type HEADACHES.,93-101-106,44-53,MIGRAINE headaches,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:39:49,,1320735894,7/11/2014 13:39:46,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,106,44,,,115,52,HEADACHES,MIGRAINE,with tension type HEADACHES.,88-93-101-106,27-30-39-44-53-63-67,of patients with MIGRAINE headaches and in,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:41:08,,1320736336,7/11/2014 13:41:00,clixsense,1.0,9343409,NLD,"","",194.120.71.114,106,44,,,115,52,HEADACHES,MIGRAINE,migraine headaches with tension type HEADACHES.,44-88-93-101-106-53,27-30-39-44-53-63-67-93-101-106,of patients with MIGRAINE headaches and in tension type headaches.,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:48:42,,1320739183,7/11/2014 13:48:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,106,44,,,115,52,HEADACHES,MIGRAINE,migraine headaches tension type HEADACHES.,44-53-93-101-106,44-53-93-101-106,MIGRAINE headaches tension type headaches.,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:54:04,,1320740961,7/11/2014 13:53:44,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,106,44,,,115,52,HEADACHES,MIGRAINE,migraine headaches tension type HEADACHES.,44-53-93-101-106,44-53-93-101-106,MIGRAINE headaches tension type headaches.,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:55:44,,1320741454,7/11/2014 13:55:24,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,106,44,,,115,52,HEADACHES,MIGRAINE,tension type HEADACHES.,93-101-106,44-53,MIGRAINE headaches,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:57:28,,1320742013,7/11/2014 13:56:58,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,106,44,,,115,52,HEADACHES,MIGRAINE,HEADACHES.,106,44,MIGRAINE,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 13:58:58,,1320742597,7/11/2014 13:58:40,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,106,44,,,115,52,HEADACHES,MIGRAINE,HEADACHES.,106,44,MIGRAINE,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249562,7/11/2014 14:03:02,,1320744311,7/11/2014 14:02:49,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,106,44,,,115,52,HEADACHES,MIGRAINE,tension type HEADACHES.,93-101-106,44-53,MIGRAINE headaches,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches.,106,44,106,44,115,52,-1,RO-has_definitional_manifestation,904839,IL-4 was detected in 17.1% of patients with migraine headaches and in 28.6% of patients with tension-type headaches,headaches,migraine
502249563,7/11/2014 13:39:50,,1320735904,7/11/2014 13:38:59,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120-132-147,TOTAL hepatocellular carcinomas,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 13:43:31,,1320737213,7/11/2014 13:43:01,clixsense,1.0,9343409,NLD,"","",194.120.71.114,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,total of 18 HEPATOCELLULAR CARCINOMAS in non cirrhotic chronic hepatitis C infection.,120-126-129-132-147-158-161-165-195-205-207-187,102-107-118-120-126-129-132-187-195-205-207,2008 identified a TOTAL of 18 hepatocellular chronic hepatitis C infection.,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 13:49:00,,1320739290,7/11/2014 13:48:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120,TOTAL,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 13:59:19,,1320742749,7/11/2014 13:58:59,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120,TOTAL,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:04:05,,1320744777,7/11/2014 14:03:52,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120,TOTAL,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:07:06,,1320746062,7/11/2014 14:06:48,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS non cirrhotic,132-147-161-165,120-132,TOTAL hepatocellular,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:07:41,,1320746306,7/11/2014 14:07:10,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120-126-129-132-147,TOTAL of 18 hepatocellular carcinomas,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:08:44,,1320746808,7/11/2014 14:08:00,vivatic,1.0,25451531,GBR,"","",83.67.28.193,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,118-120-126-129-132-147,a TOTAL of 18 hepatocellular carcinomas,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:10:00,,1320747322,7/11/2014 14:09:42,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS -,132-147-164,120-126-129-132-147,TOTAL of 18 hepatocellular carcinomas,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249563,7/11/2014 14:10:00,,1320747326,7/11/2014 14:09:41,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,132,120,,,157,125,HEPATOCELLULAR CARCINOMAS,TOTAL,HEPATOCELLULAR CARCINOMAS,132-147,120,TOTAL,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection.",132 147,120,132,120,157,125,-1,RO-has_manifestation,906116,"However, a search of surgical pathology files from two large tertiary care centers for the years 2001-2008 identified a total of 18 hepatocellular carcinomas in non-cirrhotic livers with chronic hepatitis C infection",hepatocellular carcinomas,total
502249564,7/11/2014 13:38:09,,1320735364,7/11/2014 13:38:00,clixsense,1.0,9343409,NLD,"","",194.120.71.114,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,fluoxetine the treatment of OBSESSIVE COMPULSIVE DISORDER.,65-69-79-82-92-103-51,33-42-48-51-62-65-69-82-92-103,clinical trial of FLUOXETINE in the treatment obsessive compulsive disorder.,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:40:29,,1320736110,7/11/2014 13:40:16,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:45:13,,1320737788,7/11/2014 13:44:57,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,the treatment of OBSESSIVE COMPULSIVE DISORDER.,65-69-79-82-92-103,33-42-48-51-62-65-69,clinical trial of FLUOXETINE in the treatment,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:47:53,,1320738854,7/11/2014 13:47:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:49:30,,1320739465,7/11/2014 13:49:16,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,the treatment of OBSESSIVE COMPULSIVE DISORDER.,65-69-79-82-92-103,33-42-48-51-82-92-103,clinical trial of FLUOXETINE obsessive compulsive disorder.,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:53:42,,1320740832,7/11/2014 13:53:22,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,clinical trial fluoxetine OBSESSIVE COMPULSIVE DISORDER.,33-51-82-92-103-42,33-42-48-51-82-92-103,clinical trial of FLUOXETINE obsessive compulsive disorder.,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 13:56:00,,1320741514,7/11/2014 13:55:48,instagc,1.0,13763729,USA,"","",75.182.89.225,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 14:03:51,,1320744671,7/11/2014 14:03:40,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 14:06:33,,1320745850,7/11/2014 14:06:10,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249564,7/11/2014 14:08:21,,1320746644,7/11/2014 14:08:07,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,82,51,,,111,61,OBSESSIVE-COMPULSIVE DISORDER,FLUOXETINE,OBSESSIVE COMPULSIVE DISORDER.,82-92-103,51,FLUOXETINE,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.",82 92 103,51,82,51,111,61,1,RO-may_treat,907730,"Fontaine R, Chouinard G. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder",obsessive-compulsive disorder,fluoxetine
502249565,7/11/2014 13:29:10,,1320732473,7/11/2014 13:28:55,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 13:35:18,,1320734500,7/11/2014 13:34:47,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 13:44:16,,1320737467,7/11/2014 13:43:41,clixsense,1.0,9343409,NLD,"","",194.120.71.114,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,"oxidative stress, exaggeration considered important in PREGNANCY COMPLICATIONS such as preeclampsia.",39-49-97-108-118-121-131-145-150-153-61,131-145-150-153,complications such as PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:01:02,,1320743497,7/11/2014 14:00:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:03:23,,1320744456,7/11/2014 14:03:09,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:06:04,,1320745629,7/11/2014 14:05:50,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:08:07,,1320746525,7/11/2014 14:07:42,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:09:20,,1320747074,7/11/2014 14:09:05,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:09:26,,1320747119,7/11/2014 14:09:10,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS,121-131,153,PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249565,7/11/2014 14:09:53,,1320747289,7/11/2014 14:09:42,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,121,153,,,144,165,PREGNANCY COMPLICATIONS,PREECLAMPSIA,PREGNANCY COMPLICATIONS such as preeclampsia.,121-131-145-150-153,131-145-150-153,complications such as PREECLAMPSIA.,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia.",121 131,153,121,153,144,165,-1,RO-disease_has_finding,901876,"Pregnancy is associated with increased oxidative stress, and exaggeration of oxidative damage is considered important in pregnancy complications such as preeclampsia",pregnancy complications,preeclampsia
502249566,7/11/2014 13:31:59,,1320733373,7/11/2014 13:31:45,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS,99,49-55,VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:34:39,,1320734317,7/11/2014 13:33:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,99,49,,,104,64,VIRUS,VIRUS INFECTION,the type of VIRUS,87-91-96-99,25-32-42-49-55,mucous transport during VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:36:47,,1320734921,7/11/2014 13:36:28,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS,99,49-55,VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:39:07,,1320735658,7/11/2014 13:39:04,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,99,49,,,104,64,VIRUS,VIRUS INFECTION,the type of VIRUS and are most,87-91-96-99-105-109-113,25-32-42-49-55-65-72-75,mucous transport during VIRUS INFECTION appear to depend,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:39:34,,1320735781,7/11/2014 13:37:58,clixsense,1.0,18408026,USA,WA,Tacoma,131.191.72.163,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS influenza A respiratory syncytial virus infection.,99-128-138-144-156-166-172,16-25-49-55-99-128-138-144-156-166-172,tracheal mucous VIRUS INFECTION virus influenza A respiratory syncytial virus infection.,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:41:42,,1320736506,7/11/2014 13:41:08,clixsense,1.0,9343409,NLD,"","",194.120.71.114,99,49,,,104,64,VIRUS,VIRUS INFECTION,tracheal mucous the type of VIRUS and are most influenza respiratory syncytial virus infection.,16-25-87-91-96-99-105-109-113-128-144-156-166-172,16-25-32-42-49-55-65-72-75-128-144-156-172,tracheal mucous transport during VIRUS INFECTION appear to depend influenza respiratory syncytial infection.,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:42:08,,1320736642,7/11/2014 13:41:50,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS,99,49-55,VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:43:57,,1320737340,7/11/2014 13:43:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS,99,49-55,VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:44:49,,1320737680,7/11/2014 13:44:17,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,99,49,,,104,64,VIRUS,VIRUS INFECTION,tracheal mucous transport VIRUS influenza A respiratory syncytial virus infection.,16-25-32-99-128-138-144-166-172-156,16-25-32-49-55-128-138-144-156-166-172,tracheal mucous transport VIRUS INFECTION influenza A respiratory syncytial virus infection.,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249566,7/11/2014 13:55:33,,1320741389,7/11/2014 13:55:08,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,99,49,,,104,64,VIRUS,VIRUS INFECTION,VIRUS,99,25-32-49-55,mucous transport VIRUS INFECTION,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection.,99,49 55,99,49,104,64,1,RO-has_causative_agent,903829,Disturbances in tracheal mucous transport during virus infection appear to depend upon the type of virus and are most severe in influenza A and respiratory syncytial virus infection,virus,virus infection
502249567,7/11/2014 13:30:18,,1320732882,7/11/2014 13:30:02,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A. approximately,76-87-99,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:31:24,,1320733214,7/11/2014 13:30:58,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A.,76-87,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:40:36,,1320736156,7/11/2014 13:40:32,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,76,26,,,86,31,HEMOPHILIA,FVIII,"the management of HEMOPHILIA A. However, approximately",58-62-73-76-87-90-99,0-12-20-26-32-35-39,Replacement therapy using FVIII is the leading,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:41:28,,1320736395,7/11/2014 13:41:14,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A.,76-87,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:41:50,,1320736564,7/11/2014 13:41:28,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A.,76-87,0-12-26,Replacement therapy FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:42:41,,1320736848,7/11/2014 13:42:29,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,76,26,,,86,31,HEMOPHILIA,FVIII,"the management of HEMOPHILIA A. However, approximately patients",58-62-73-76-87-90-99-127,0-12-20-26-32-35-39,Replacement therapy using FVIII is the leading,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:49:15,,1320739381,7/11/2014 13:49:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA,76,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:55:49,,1320741468,7/11/2014 13:54:05,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,76,26,,,86,31,HEMOPHILIA,FVIII,Replacement therapy FVIII HEMOPHILIA A. inhibitory antibodies protein.,0-12-26-76-144-155-202-87,0-12-26-76-87-144-155-202,Replacement therapy FVIII hemophilia A. inhibitory antibodies protein.,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:56:03,,1320741519,7/11/2014 13:55:34,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A.,76-87,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249567,7/11/2014 13:58:46,,1320742521,7/11/2014 13:58:18,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,76,26,,,86,31,HEMOPHILIA,FVIII,HEMOPHILIA A.,76-87,26,FVIII,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein.",76,26,76,26,86,31,-1,RO-has_manifestation,906015,"Replacement therapy using FVIII is the leading therapy in the management of hemophilia A. However, approximately 15% to 30% of patients develop inhibitory antibodies that neutralize the activity of the protein",hemophilia,FVIII
502249568,7/11/2014 13:29:46,,1320732734,7/11/2014 13:29:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53-65-73-76,SULCONAZOLE nitrate 1% cream,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:41:31,,1320736406,7/11/2014 13:41:08,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53-65,SULCONAZOLE nitrate,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:41:54,,1320736587,7/11/2014 13:41:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53-65-73-76,SULCONAZOLE nitrate 1% cream,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:44:02,,1320737379,7/11/2014 13:43:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53-65-76-73,SULCONAZOLE nitrate 1% cream,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:46:04,,1320738134,7/11/2014 13:45:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53,SULCONAZOLE,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:55:47,,1320741460,7/11/2014 13:55:31,instagc,1.0,13763729,USA,"","",75.182.89.225,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53,SULCONAZOLE,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 13:58:36,,1320742449,7/11/2014 13:58:21,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53,SULCONAZOLE,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 14:01:51,,1320743766,7/11/2014 14:01:13,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53-65-73-76,SULCONAZOLE nitrate 1% cream,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 14:08:05,,1320746511,7/11/2014 14:07:54,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,TINEA PEDIS,36-42,53,SULCONAZOLE,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249568,7/11/2014 14:08:07,,1320746532,7/11/2014 14:07:49,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,36,53,,,47,64,TINEA PEDIS,SULCONAZOLE,Treatment of TINEA PEDIS,23-36-42-33,36-42-48-53,tinea pedis with SULCONAZOLE,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream.",36 42,53,36,53,47,64,1,RO-may_treat,907886,"Woscoff A, Carabeli S. Treatment of tinea pedis with sulconazole nitrate 1% cream or miconazole nitrate 2% cream",tinea pedis,sulconazole
502249569,7/11/2014 13:40:50,,1320736238,7/11/2014 13:39:10,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,105,89,,,113,97,HEADACHE,MIGRAINE,49.8 headache,-1-362,277-337-345,headache tension type,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 13:41:00,,1320736269,7/11/2014 13:39:44,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,105,89,,,113,97,HEADACHE,MIGRAINE,Gamma aminobutyric,0-6,0-6,Gamma aminobutyric,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 13:41:39,,1320736478,7/11/2014 13:41:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,105,89,,,113,97,HEADACHE,MIGRAINE,49.8,-1,-1,49.8,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 13:45:00,,1320737732,7/11/2014 13:44:16,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,105,89,,,113,97,HEADACHE,MIGRAINE,patients with migraine,152-161-166,-1-277-337-345-407,49.8 headache tension type /,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 13:58:18,,1320742304,7/11/2014 13:57:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,105,89,,,113,97,HEADACHE,MIGRAINE,migraine,166,277,headache,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 13:58:20,,1320742322,7/11/2014 13:57:46,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,105,89,,,113,97,HEADACHE,MIGRAINE,headache,277,-1,49.8,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 14:04:55,,1320745100,7/11/2014 14:04:27,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,105,89,,,113,97,HEADACHE,MIGRAINE,Gamma aminobutyric acid,0-6-19,0-6-19-24,Gamma aminobutyric acid levels,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 14:06:17,,1320745714,7/11/2014 14:05:40,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,105,89,,,113,97,HEADACHE,MIGRAINE,49.8 migraine headache tension type,166-277-337-345--1,-1-254,49.8 headache,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 14:06:56,,1320745983,7/11/2014 14:06:44,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,105,89,,,113,97,HEADACHE,MIGRAINE,49.8,-1,-1,49.8,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249569,7/11/2014 14:07:09,,1320746078,7/11/2014 14:06:09,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,105,89,,,113,97,HEADACHE,MIGRAINE,headache tension type,337-345-277,-1,49.8,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls.",,,105,89,113,97,-1,RO-has_definitional_manifestation,904663,"Gamma-aminobutyric acid levels in saliva were 36.8 +/- 49.8 pmol/mL in the patients with migraine during headache attacks, 17.9 +/- 25.2 pmol/mL in the patients with migraine in interictal periods, 16.0 +/- 18.3 pmol/mL in the patients with tension-type headache during active headache periods, 14.1 +/- 6.8 pmol/mL in the patients with tension-type headache in headache-free periods, and 21.6 +/- 22.7 pmol/mL in the healthy controls",headache,migraine
502249570,7/11/2014 13:39:13,,1320735691,7/11/2014 13:38:41,clixsense,1.0,9343409,NLD,"","",194.120.71.114,73,88,,,84,95,ASSOCIATION,OBESITY,adipose tissue and the ASSOCIATION of obesity with,58-65-69-73-85-88-96-50,69-73-85-88-96-101-109,the association of OBESITY with chronic low,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 13:42:10,,1320736648,7/11/2014 13:41:50,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION of obesity,73-85-88,88-96-101-109,OBESITY with chronic low,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 13:45:10,,1320737772,7/11/2014 13:44:55,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION of obesity,73-85-88,88,OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 13:46:15,,1320738213,7/11/2014 13:46:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION,73,88,OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 13:47:24,,1320738676,7/11/2014 13:46:38,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,73,88,,,84,95,ASSOCIATION,OBESITY,endocrine function adipose tissue ASSOCIATION obesity chronic low - grade inflammation adipose tissue adipose tissue obesity linked insulin resistance metabolic dysregulation.,28-50-58-73-88-101-109-112-113-119-135-143-200-208-228-236-243-251-266-276-38,28-38-50-58-73-88-101-109-113-119-135-143-200-208-228-236-243-251-266-276,endocrine function adipose tissue association OBESITY chronic low grade inflammation adipose tissue adipose tissue obesity linked insulin resistance metabolic dysregulation.,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 13:55:31,,1320741379,7/11/2014 13:55:09,instagc,1.0,13763729,USA,"","",75.182.89.225,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION,73,88,OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 14:03:23,,1320744452,7/11/2014 14:02:48,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION of obesity,73-85-88,73-85-88,association of OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 14:09:02,,1320746945,7/11/2014 14:08:31,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION,73,88,OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 14:09:40,,1320747191,7/11/2014 14:09:27,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,73,88,,,84,95,ASSOCIATION,OBESITY,ASSOCIATION of obesity,73-85-88,73-85-88,association of OBESITY,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249570,7/11/2014 14:10:26,,1320747468,7/11/2014 14:10:22,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,73,88,,,84,95,ASSOCIATION,OBESITY,tissue and the ASSOCIATION of obesity with,58-65-69-73-85-88-96,69-73-85-88-96-101-109,the association of OBESITY with chronic low,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation.,73,88,73,88,84,95,-1,RO-has_definitional_manifestation,904676,The recent discovery of the endocrine function of adipose tissue and the association of obesity with chronic low-grade inflammation in adipose tissue has reinforced the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance and metabolic dysregulation,association,obesity
502249571,7/11/2014 13:33:32,,1320733962,7/11/2014 13:33:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Hopkins LUPUS Cohort perspective,62-70-76-83,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:34:24,,1320734264,7/11/2014 13:33:56,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,70,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:40:32,,1320736126,7/11/2014 13:40:28,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,erythematosus: the Hopkins LUPUS Cohort perspective,43-58-62-70-76-83,10-13-24-28-37-43-58-62-70,M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the Hopkins Lupus,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:42:55,,1320736983,7/11/2014 13:42:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,70,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:43:27,,1320737192,7/11/2014 13:43:12,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Hopkins LUPUS Cohort perspective,62-70-76-83,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:44:56,,1320737699,7/11/2014 13:44:17,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,erythematosus: the Hopkins LUPUS Cohort perspective,43-58-62-70-76-83,10-13-24-28-37-43-58-62-70,M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the Hopkins Lupus,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 13:56:35,,1320741718,7/11/2014 13:56:09,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Petri M. Thrombosis systemic lupus LUPUS,4-10-13-28-37-70,4-10-13-28-37-43-70,Petri M. Thrombosis SYSTEMIC LUPUS ERYTHEMATOSUS: Lupus,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 14:00:23,,1320743144,7/11/2014 13:59:45,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Hopkins LUPUS Cohort,62-70-76,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 14:06:32,,1320745847,7/11/2014 14:06:16,clixsense,1.0,9343409,NLD,"","",194.120.71.114,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic lupus erythematosus: the Hopkins LUPUS Cohort perspective,28-43-58-62-70-76-83-37,10-13-24-28-37-43-58-62-70-76-83,M. Thrombosis and SYSTEMIC LUPUS ERYTHEMATOSUS: the Hopkins Lupus Cohort perspective,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249571,7/11/2014 14:06:47,,1320745914,7/11/2014 14:06:25,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,70,28,,,75,56,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Hopkins LUPUS Cohort perspective,62-70-76-83,28-37-43,SYSTEMIC LUPUS ERYTHEMATOSUS:,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial.,70,28 37 43,70,28,75,56,-1,RO-has_manifestation,906077,2]  Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective [Editorial,Lupus,systemic lupus erythematosus
502249572,7/11/2014 13:41:27,,1320736391,7/11/2014 13:41:08,clixsense,1,6355877,GBR,I7,Newcastle,77.98.220.230,56,18,,,65,21,ALLERGIES,ONE,ALLERGIES,56,0-7-18,Peanut allergy ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 13:42:54,,1320736969,7/11/2014 13:42:28,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,56,18,,,65,21,ALLERGIES,ONE,food ALLERGIES,51-56,18,ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 13:45:59,,1320738114,7/11/2014 13:45:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,56,18,,,65,21,ALLERGIES,ONE,Peanut allergy life threatening food ALLERGIES,0-7-34-39-51-56,0-7-15-18-22-25-29,Peanut allergy is ONE of the most,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 13:51:50,,1320740200,7/11/2014 13:51:31,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,56,18,,,65,21,ALLERGIES,ONE,Peanut allergy food ALLERGIES,0-7-51-56,0-7-18-51-56,Peanut allergy ONE food allergies,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:05:45,,1320745486,7/11/2014 14:04:51,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,56,18,,,65,21,ALLERGIES,ONE,ALLERGIES,56,18,ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:07:49,,1320746359,7/11/2014 14:07:27,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,56,18,,,65,21,ALLERGIES,ONE,food ALLERGIES,51-56,18,ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:08:02,,1320746485,7/11/2014 14:07:30,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,56,18,,,65,21,ALLERGIES,ONE,food ALLERGIES,51-56,18,ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:09:27,,1320747120,7/11/2014 14:09:10,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,56,18,,,65,21,ALLERGIES,ONE,life threatening food ALLERGIES,34-39-51-56,0-7-15-18-22-25-29-34-39-51-56,Peanut allergy is ONE of the most life threatening food allergies,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:10:22,,1320747447,7/11/2014 14:10:11,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,56,18,,,65,21,ALLERGIES,ONE,food ALLERGIES,51-56,0-7-15-18,Peanut allergy is ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249572,7/11/2014 14:10:32,,1320747512,7/11/2014 14:10:15,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,56,18,,,65,21,ALLERGIES,ONE,life threatening food ALLERGIES,34-39-51-56,18,ONE,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries.,56,18,56,18,65,21,-1,RO-cause_of,900475,Peanut allergy is one of the most life-threatening food allergies and one of the serious challenges facing the peanut and food industries,allergies,one
502249573,7/11/2014 13:39:10,,1320735663,7/11/2014 13:38:51,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"from work related ALLERGY, including immediate and",56-61-66-74-83-93-103,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 13:45:33,,1320737901,7/11/2014 13:45:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"ALLERGY,",74,107-114-115-120,"delayed - type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 13:53:18,,1320740706,7/11/2014 13:52:00,bitcoinget,1,27788878,USA,IL,Itasca,67.152.129.18,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"work related ALLERGY,",61-74-66,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 13:56:10,,1320741557,7/11/2014 13:55:44,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"work related ALLERGY,",61-66-74,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:00:00,,1320742999,7/11/2014 13:59:42,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"ALLERGY,",74,120,"HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:07:08,,1320746070,7/11/2014 14:06:49,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"work related ALLERGY,",61-66-74,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:08:06,,1320746518,7/11/2014 14:07:50,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"work related ALLERGY,",61-66-74,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:09:31,,1320747142,7/11/2014 14:09:22,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"ALLERGY,",74,120,"HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:10:10,,1320747367,7/11/2014 14:10:06,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"from work related ALLERGY, including immediate and",56-61-66-74-83-93-103,103-107-115-120-140-144-155,"and delayed type HYPERSENSITIVITIES, are considered and","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249573,7/11/2014 14:11:33,,1320747905,7/11/2014 14:11:20,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,74,120,,,81,138,ALLERGY,HYPERSENSITIVITIES,"ALLERGY,",74,107-115-120,"delayed type HYPERSENSITIVITIES,","In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed.",74,120,74,120,81,138,-1,RO-cause_of,900222,"In this chapter, various methods of protecting a worker from work-related allergy, including immediate and delayed-type hypersensitivities, are considered and reviewed",allergy,hypersensitivities
502249574,7/11/2014 13:31:45,,1320733316,7/11/2014 13:31:25,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:32:25,,1320733520,7/11/2014 13:31:53,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:38:51,,1320735556,7/11/2014 13:38:36,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:39:54,,1320735917,7/11/2014 13:39:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:41:05,,1320736295,7/11/2014 13:40:52,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,hemolytic anemia and THROMBOCYTOPENIA in the absence,97-107-114-118-135-138-142,77-80-97-107-114-118,of MICROANGIOPATHIC HEMOLYTIC ANEMIA and thrombocytopenia,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:41:51,,1320736578,7/11/2014 13:41:39,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:46:37,,1320738347,7/11/2014 13:46:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:47:40,,1320738783,7/11/2014 13:47:25,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,hemolytic anemia and THROMBOCYTOPENIA in the absence,97-107-114-118-135-138-142,65-68-77-80-97-107-114-118-135,on evidence of MICROANGIOPATHIC HEMOLYTIC ANEMIA and thrombocytopenia in,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 13:48:05,,1320738928,7/11/2014 13:47:46,instagc,1.0,13763729,USA,"","",75.182.89.225,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249574,7/11/2014 14:00:08,,1320743050,7/11/2014 13:59:51,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,118,80,,,134,113,THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA,THROMBOCYTOPENIA,118,80-97-107,MICROANGIOPATHIC HEMOLYTIC ANEMIA,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy.,118,80 97 107,118,80,134,113,-1,RO-has_manifestation,906432,The diagnosis of thrombotic thrombocytopenic purpura (TTP) rests on evidence of microangiopathic hemolytic anemia and thrombocytopenia in the absence of disseminated intravascular coagulation and other known causes of thrombotic microangiopathy,thrombocytopenia,microangiopathic hemolytic anemia
502249575,7/11/2014 13:32:16,,1320733496,7/11/2014 13:31:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,178-184,BINGE programme,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:37:59,,1320735296,7/11/2014 13:37:48,clixsense,1.0,9343409,NLD,"","",194.120.71.114,219,178,,,231,183,BINGE EATING,BINGE,subjects affected by BINGE EATING patients.,198-207-216-219-225-237,168-170-173-178-184-194-198,a 20 week BINGE programme for subjects,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:39:11,,1320735665,7/11/2014 13:39:08,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,219,178,,,231,183,BINGE EATING,BINGE,subjects affected by BINGE EATING patients.,198-207-216-219-225-237,168-170-173-178-184-194-198,a 20 week BINGE programme for subjects,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:40:49,,1320736232,7/11/2014 13:40:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,170-172-173-178-184,20 - week BINGE programme,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:40:53,,1320736253,7/11/2014 13:40:33,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,178-184,BINGE programme,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:41:13,,1320736352,7/11/2014 13:41:00,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,178,BINGE,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:42:05,,1320736615,7/11/2014 13:41:31,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,219,178,,,231,183,BINGE EATING,BINGE,subjects affected by BINGE EATING patients.,198-207-216-219-225-237,168-170-173-178-219-225,a 20 week BINGE binge eating,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:46:33,,1320738324,7/11/2014 13:45:56,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,219,178,,,231,183,BINGE EATING,BINGE,subjects affected by BINGE EATING patients.,198-207-216-219-225-237,168-170-173-178-184-194-198,a 20 week BINGE programme for subjects,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:46:55,,1320738465,7/11/2014 13:46:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,178,BINGE,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249575,7/11/2014 13:52:16,,1320740314,7/11/2014 13:51:56,instagc,1.0,13763729,USA,"","",75.182.89.225,219,178,,,231,183,BINGE EATING,BINGE,BINGE EATING,219-225,178,BINGE,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients.",219 225,178,219,178,231,183,-1,RO-has_definitional_manifestation,904800,"The patients were enrolled into three different programmes: a 14-week LEARN programme (672 patients), a 16-week MOB programme for the morbidly obese (259 patients), or a 20-week BINGE programme for subjects affected by binge eating (137 patients",binge eating,BINGE
502249576,7/11/2014 13:27:34,,1320731965,7/11/2014 13:27:15,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 13:42:27,,1320736781,7/11/2014 13:42:17,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,manifested commonly by LEUKOPENIA granulocytopenia); 1,249-260-269-272-296-316,269-272-283-296-316-322-328,by leukopenia (principally GRANULOCYTOPENIA); 1 2 17,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 13:59:19,,1320742746,7/11/2014 13:58:41,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:01:16,,1320743574,7/11/2014 14:00:51,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:02:27,,1320744031,7/11/2014 14:02:03,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:05:05,,1320745222,7/11/2014 14:04:43,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA granulocytopenia);,272-296,272-296,leukopenia GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:07:26,,1320746209,7/11/2014 14:06:58,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:08:50,,1320746853,7/11/2014 14:08:38,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA,272,296,GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:09:21,,1320747070,7/11/2014 14:09:11,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA granulocytopenia); 1,272-296-316,272-296,leukopenia GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249576,7/11/2014 14:12:15,,1320748198,7/11/2014 14:11:47,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,272,296,,,282,312,LEUKOPENIA,GRANULOCYTOPENIA,LEUKOPENIA (principally granulocytopenia);,272-283-296,272-283-296,leukopenia (principally GRANULOCYTOPENIA);,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may.",272,296,272,296,282,312,-1,RO-has_definitional_manifestation,904665,"1 ,   2 ,   189 ,   256  Warnings/Precautions  Warnings  Myelosuppression  Risk of dose-limiting and potentially fatal myelosuppression,  1 ,   2 ,   17 ,   59 ,   64 ,   106 ,   110 ,   116 ,   118 ,   120 ,   133 ,   134 ,   135 ,   136 ,   256   manifested commonly by leukopenia (principally granulocytopenia);  1 ,   2 ,   17 ,   57 ,   59 ,   64 ,   67 ,   91 ,   100 ,   101 ,   256   thrombocytopenia   1 ,   2 ,   17 ,   64 ,   67 ,   91 ,   100 ,   101   and anemia may",leukopenia,granulocytopenia
502249577,7/11/2014 13:37:29,,1320735150,7/11/2014 13:37:21,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 13:40:50,,1320736239,7/11/2014 13:40:30,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 13:42:31,,1320736795,7/11/2014 13:42:14,clixsense,1.0,9343409,NLD,"","",194.120.71.114,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,appearance of nonthrombocytic PURPURA is an important,4-15-18-34-42-45-48,18-67-71-81-84-91-101-34,nonthrombocytic purpura the diagnosis of HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 13:53:46,,1320740843,7/11/2014 13:53:33,instagc,1.0,13763729,USA,"","",75.182.89.225,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,PURPURA,34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 13:57:03,,1320741869,7/11/2014 13:56:46,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,PURPURA,34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 14:06:27,,1320745801,7/11/2014 14:05:13,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 14:06:55,,1320745961,7/11/2014 14:06:04,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101-109,HENOCH SCHONLEIN PURPURA (HSP.,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 14:09:04,,1320746965,7/11/2014 14:08:49,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101-109,HENOCH SCHONLEIN PURPURA (HSP.,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 14:09:09,,1320746993,7/11/2014 14:08:51,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101,HENOCH SCHONLEIN PURPURA,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249577,7/11/2014 14:09:28,,1320747130,7/11/2014 14:09:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,34,84,,,41,108,PURPURA,HENOCH-SCHONLEIN PURPURA,nonthrombocytic PURPURA,18-34,84-91-101-109,HENOCH SCHONLEIN PURPURA (HSP.,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP.,34,84 91 101,34,84,41,108,-1,RO-has_definitional_manifestation,904727,The appearance of nonthrombocytic purpura is an important clue for the diagnosis of Henoch-Schonlein purpura (HSP,purpura,Henoch-Schonlein purpura
502249578,7/11/2014 13:33:15,,1320733889,7/11/2014 13:32:58,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,184,161,,,190,170,JOINTS,ARTHRITIS,small JOINTS of the hands,178-184-191-194-198,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:33:19,,1320733895,7/11/2014 13:32:26,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS,184,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:36:53,,1320734933,7/11/2014 13:36:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS of the hands,184-191-194-198,42-50-61-66-70-81-84-91-94-98-161-110,"morning stiffness, pain and limitation of motion of the dorsolumbar spine ARTHRITIS","The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:39:27,,1320735739,7/11/2014 13:39:25,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,184,161,,,190,170,JOINTS,ARTHRITIS,of the small JOINTS of the hands,171-174-178-184-191-194-198,136-145-156-161-171-174-178,"members, associated with ARTHRITIS of the small","The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:40:55,,1320736254,7/11/2014 13:40:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS,184,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:50:02,,1320739629,7/11/2014 13:49:31,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS of the hands shoulder periarthritis two costal cartilage,184-191-194-198-214-223-240-248-255,98-161-110,dorsolumbar spine ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 13:54:40,,1320741100,7/11/2014 13:54:18,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS,184,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 14:00:23,,1320743143,7/11/2014 13:59:58,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,184,161,,,190,170,JOINTS,ARTHRITIS,arthritis of the small JOINTS of the hands,161-174-178-184-191-194-198-171,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 14:00:48,,1320743354,7/11/2014 14:00:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS,184,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249578,7/11/2014 14:00:55,,1320743421,7/11/2014 13:59:57,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,184,161,,,190,170,JOINTS,ARTHRITIS,JOINTS,184,161,ARTHRITIS,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one.",184,161,184,161,190,170,1,RO-disease_has_primary_anatomic_site,902259,"The clinical features of the disease were morning stiffness, pain and limitation of motion of the dorsolumbar spine in four of the five members, associated with arthritis of the small joints of the hands in three, shoulder periarthritis in two and costal cartilage pain in one",joints,arthritis
502249579,7/11/2014 13:34:29,,1320734271,7/11/2014 13:34:07,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 13:37:47,,1320735222,7/11/2014 13:37:30,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 13:48:00,,1320738915,7/11/2014 13:47:25,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,182,143,,,186,156,BONE,OSTEOMYELITIS,"infections, glycopeptide antibiotics osteomyelitis, infection BONE",76-89-143-161-182-64,64-76-143-161-89,"infections, glycopeptide antibiotics OSTEOMYELITIS, infection","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:01:41,,1320743715,7/11/2014 14:01:21,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:06:22,,1320745773,7/11/2014 14:05:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:08:38,,1320746749,7/11/2014 14:08:21,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:09:05,,1320746969,7/11/2014 14:08:50,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,182,143,,,186,156,BONE,OSTEOMYELITIS,BONE,182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:09:52,,1320747271,7/11/2014 14:09:42,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,182,143,,,186,156,BONE,OSTEOMYELITIS,infection located in BONE,161-171-179-182,143-158-161,"OSTEOMYELITIS, an infection","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:10:21,,1320747439,7/11/2014 14:10:17,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,182,143,,,186,156,BONE,OSTEOMYELITIS,infection located in BONE and notoriously difficult,161-171-179-182-187-191-203,131-134-140-143-158-161-171,"in cases of OSTEOMYELITIS, an infection located","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249579,7/11/2014 14:10:26,,1320747474,7/11/2014 14:10:07,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,182,143,,,186,156,BONE,OSTEOMYELITIS,infection located in BONE,161-171-179-182,143,"OSTEOMYELITIS,","As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage.",182,143,182,143,186,156,1,RO-disease_has_primary_anatomic_site,902077,"As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage",bone,osteomyelitis
502249580,7/11/2014 13:39:20,,1320735719,7/11/2014 13:39:18,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,273,209,,,278,217,DRUGS,OVERDOSE,antibiotics or other DRUGS that interfere with,252-264-267-273-279-284-294,186-198-204-209-218-222-239,tachycardia after both OVERDOSE and coadministration of,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:39:50,,1320735899,7/11/2014 13:37:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,273,209,,,278,217,DRUGS,OVERDOSE,antibiotics or other DRUGS,252-264-267-273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:43:16,,1320737104,7/11/2014 13:42:55,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:44:09,,1320737433,7/11/2014 13:43:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:53:21,,1320740733,7/11/2014 13:52:28,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,273,209,,,278,217,DRUGS,OVERDOSE,nonsedating antihistamines terfenadine astemizole QT interval atypical (torsade de pointes) ventricular tachycardia overdose coadministration macrolide antibiotics DRUGS interfere,15-27-42-58-110-113-144-153-162-165-174-186-222-242-252-273-284-209,15-27-42-58-110-113-144-153-162-165-174-186-209-222-239-242-252-273,nonsedating antihistamines terfenadine astemizole QT interval atypical (torsade de pointes) ventricular tachycardia OVERDOSE coadministration of macrolide antibiotics drugs,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:54:03,,1320740958,7/11/2014 13:53:47,instagc,1.0,13763729,USA,"","",75.182.89.225,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 13:57:50,,1320742124,7/11/2014 13:57:11,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 14:01:31,,1320743668,7/11/2014 14:00:56,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 14:06:06,,1320745665,7/11/2014 14:05:54,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,273,209,,,278,217,DRUGS,OVERDOSE,DRUGS,273,209,OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249580,7/11/2014 14:08:31,,1320746730,7/11/2014 14:08:08,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,273,209,,,278,217,DRUGS,OVERDOSE,antibiotics or other DRUGS,252-264-267-273,186-209,tachycardia OVERDOSE,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination.,273,209,273,209,278,217,1,RO-has_causative_agent,903891,65   The older nonsedating antihistamines terfenadine and astemizole were associated with prolongation of the QT interval and the occurrence of atypical (torsade de pointes) ventricular tachycardia after both overdose and coadministration of macrolide antibiotics or other drugs that interfere with their elimination,drugs,overdose
502249581,7/11/2014 13:34:43,,1320734348,7/11/2014 13:34:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,97-103-111-121,large primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:37:48,,1320735239,7/11/2014 13:37:22,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,103-111-121,primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:38:59,,1320735600,7/11/2014 13:36:50,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,cutaneous melanosis NEUROLOGICAL SYMPTOMS,27-66-79-37,95-97-103-111-121,a large primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:39:14,,1320735692,7/11/2014 13:39:11,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,who presented with NEUROLOGICAL SYMPTOMS due to a,47-51-61-66-79-88-92-95,95-97-103-111-121,a large primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:43:04,,1320737032,7/11/2014 13:42:53,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,111-121,MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:44:41,,1320737621,7/11/2014 13:44:30,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,103-111-121,primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 13:47:17,,1320738639,7/11/2014 13:47:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,111-121,MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 14:05:18,,1320745284,7/11/2014 14:05:10,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,103-111-121,primary MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 14:08:20,,1320746629,7/11/2014 14:08:07,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,111-121,MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249581,7/11/2014 14:08:30,,1320746729,7/11/2014 14:08:08,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,66,111,,,87,129,NEUROLOGICAL SYMPTOMS,MENINGEAL MELANOMA,NEUROLOGICAL SYMPTOMS,66-79,111-121,MENINGEAL MELANOMA.,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma.,66 79,111 121,66,111,87,129,1,RO-disease_may_have_finding,902605,We describe a patient with cutaneous melanosis who presented with neurological symptoms due to a large primary meningeal melanoma,neurological symptoms,meningeal melanoma
502249582,7/11/2014 13:31:00,,1320733128,7/11/2014 13:30:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19-33,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs),"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 13:41:23,,1320736379,7/11/2014 13:40:48,clixsense,1.0,18408026,USA,WA,Tacoma,131.191.72.163,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations CNS vascular anomalies SEIZURES, cerebral lesions.",0-9-19-44-48-57-83-151-160,0-9-19-44-48-57,CEREBRAL CAVERNOUS MALFORMATIONS CNS vascular anomalies,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 13:43:05,,1320737033,7/11/2014 13:42:57,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 13:45:19,,1320737824,7/11/2014 13:45:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 13:51:31,,1320740067,7/11/2014 13:51:11,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) CNS vascular SEIZURES, headaches and hemorrhagic strokes cerebral lesions.",0-9-19-33-44-48-83-93-103-107-119-151-160,0-9-19-40-44-48-57-83-93-107-119-151-160,"CEREBRAL CAVERNOUS MALFORMATIONS are CNS vascular anomalies seizures, headaches hemorrhagic strokes cerebral lesions.","Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 13:54:49,,1320741165,7/11/2014 13:54:36,instagc,1.0,13763729,USA,"","",75.182.89.225,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 14:05:37,,1320745450,7/11/2014 14:05:25,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19-33,CEREBRAL CAVERNOUS MALFORMATIONS (CCMs),"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 14:06:47,,1320745923,7/11/2014 14:06:27,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 14:07:37,,1320746267,7/11/2014 14:07:25,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"SEIZURES,",83,0-9-19,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249582,7/11/2014 14:10:38,,1320747537,7/11/2014 14:08:59,clixsense,1.0,9343409,NLD,"","",194.120.71.114,83,0,,,91,32,SEIZURES,CEREBRAL CAVERNOUS MALFORMATIONS,"Cerebral cavernous malformations vascular anomalies associated with SEIZURES, headaches and hemorrhagic cerebral lesions.",0-9-19-57-67-78-83-93-103-107-151-160-48,0-9-19-40-44-57-67-83-93-107-119-48,"CEREBRAL CAVERNOUS MALFORMATIONS are CNS vascular anomalies associated seizures, headaches hemorrhagic strokes","Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions.",83,0 9 19,83,0,91,32,1,RO-has_manifestation,906281,"Cerebral cavernous malformations (CCMs) are CNS vascular anomalies associated with seizures, headaches and hemorrhagic strokes and represent 10-20% of cerebral lesions",seizures,Cerebral cavernous malformations
502249583,7/11/2014 13:39:38,,1320735810,7/11/2014 13:39:35,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,inflammatory disease of GASTROINTESTINAL TRACT.,100-113-121-124-141,0-4-9-22-28-42-53,The term INFLAMMATORY BOWEL DISEASE represents different,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 13:45:55,,1320738103,7/11/2014 13:45:43,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,inflammatory disease of GASTROINTESTINAL TRACT.,100-113-121-124-141,0-4-9-22-28-42-53,The term INFLAMMATORY BOWEL DISEASE represents different,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 13:48:33,,1320739153,7/11/2014 13:48:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28,INFLAMMATORY BOWEL DISEASE,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:00:28,,1320743184,7/11/2014 14:00:09,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28,INFLAMMATORY BOWEL DISEASE,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:03:51,,1320744662,7/11/2014 14:03:36,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28,INFLAMMATORY BOWEL DISEASE,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:04:53,,1320745091,7/11/2014 14:04:34,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,chronic inflammatory disease of GASTROINTESTINAL TRACT.,100-113-121-124-141-92,9-22-28-36,INFLAMMATORY BOWEL DISEASE (IBD),The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:05:24,,1320745328,7/11/2014 14:05:10,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28-36,INFLAMMATORY BOWEL DISEASE (IBD),The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:06:08,,1320745666,7/11/2014 14:05:46,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28,INFLAMMATORY BOWEL DISEASE,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:08:21,,1320746643,7/11/2014 14:08:10,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,GASTROINTESTINAL TRACT.,124-141,9-22-28,INFLAMMATORY BOWEL DISEASE,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249583,7/11/2014 14:08:46,,1320746816,7/11/2014 14:08:32,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,124,9,,,146,35,GASTROINTESTINAL TRACT,INFLAMMATORY BOWEL DISEASE,inflammatory disease of GASTROINTESTINAL TRACT.,100-113-121-124-141,9-22-28-53-36,INFLAMMATORY BOWEL DISEASE (IBD) different,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract.,124 141,9 22 28,124,9,146,35,1,RO-has_finding_site,905078,The term inflammatory bowel disease (IBD) represents different phenotypes of the idiopathic chronic inflammatory disease of gastrointestinal tract,gastrointestinal tract,inflammatory bowel disease
502249584,7/11/2014 13:40:39,,1320736182,7/11/2014 13:40:35,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,compatible with a NEUROENDOCRINE DIFFERENTIATION status can be,71-82-87-89-104-120-127-131,28-33-44-51-62-71,lung carcinomas (SCLC) phenotypic features compatible,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 13:43:37,,1320737252,7/11/2014 13:43:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,44,(SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 13:47:24,,1320738680,7/11/2014 13:46:34,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,compatible with a NEUROENDOCRINE DIFFERENTIATION status can be,71-82-87-89-104-120-127-131,28-33-44-51-62-71,lung carcinomas (SCLC) phenotypic features compatible,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 13:50:15,,1320739701,7/11/2014 13:49:39,instagc,1.0,13763729,USA,"","",75.182.89.225,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,44,(SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 13:56:57,,1320741839,7/11/2014 13:55:19,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,17-23-28-33-44,small cell lung carcinomas (SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 14:04:41,,1320745018,7/11/2014 14:04:13,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,17-28-33-44-23,small cell lung carcinomas (SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 14:05:25,,1320745344,7/11/2014 14:04:59,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,17-23-28-33-44,small cell lung carcinomas (SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 14:07:50,,1320746364,7/11/2014 14:07:30,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,23-28-33-44,cell lung carcinomas (SCLC),In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 14:08:02,,1320746486,7/11/2014 14:06:33,clixsense,1.0,9343409,NLD,"","",194.120.71.114,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,small cell lung carcinomas phenotypic features compatible with a NEUROENDOCRINE DIFFERENTIATION status can be antibody based immunohistological procedures.,17-23-28-33-51-62-71-82-87-89-104-120-127-131-165-174-199-180,28-33-44-51-62-71-89-104-148-165-180-199-174,lung carcinomas (SCLC) phenotypic features compatible neuroendocrine differentiation monoclonal antibody based immunohistological procedures.,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249584,7/11/2014 14:09:41,,1320747195,7/11/2014 14:09:32,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,89,45,,,119,49,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,89-104,28-33-44-51,lung carcinomas (SCLC) phenotypic,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures.,89 104,,89,45,119,49,-1,RO-disease_has_finding,901753,In most cases of small-cell lung carcinomas (SCLC) phenotypic features compatible with a neuroendocrine differentiation status can be identified by monoclonal (MOC) antibody-based immunohistological procedures,neuroendocrine differentiation,SCLC
502249585,7/11/2014 13:32:43,,1320733659,7/11/2014 13:32:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,338,353,,,347,361,HEADACHES,MIGRAINE,"tension HEADACHES,",330-338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:33:55,,1320734055,7/11/2014 13:33:20,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,338,353,,,347,361,HEADACHES,MIGRAINE,"HEADACHES,",338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:42:49,,1320736905,7/11/2014 13:42:12,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,338,353,,,347,361,HEADACHES,MIGRAINE,"cluster headaches, tension HEADACHES,",311-319-330-338,330-338-349-353,"tension headaches, and MIGRAINE;","DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:43:02,,1320737021,7/11/2014 13:42:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,338,353,,,347,361,HEADACHES,MIGRAINE,"tension HEADACHES,",330-338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:43:39,,1320737256,7/11/2014 13:43:32,clixsense,1.0,9343409,NLD,"","",194.120.71.114,338,353,,,347,361,HEADACHES,MIGRAINE,"cluster headaches, tension HEADACHES, and migraine; scanning",311-319-330-338-349-353-363,330-338-349-353-363-372-382,"tension headaches, and MIGRAINE; scanning reference lists","DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:54:20,,1320741031,7/11/2014 13:52:23,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,338,353,,,347,361,HEADACHES,MIGRAINE,"headache, headache disorders, cluster headaches, tension HEADACHES, and migraine;",291-300-311-319-330-338-349-353-281,281-291-300-311-319-330-338-349-353,"headache, headache disorders, cluster headaches, tension headaches, and MIGRAINE;","DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 13:59:56,,1320742974,7/11/2014 13:59:20,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,338,353,,,347,361,HEADACHES,MIGRAINE,"tension HEADACHES,",330-338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 14:04:12,,1320744806,7/11/2014 14:03:52,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,338,353,,,347,361,HEADACHES,MIGRAINE,"HEADACHES,",338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 14:06:43,,1320745898,7/11/2014 14:06:34,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,338,353,,,347,361,HEADACHES,MIGRAINE,"cluster headaches, tension HEADACHES, and migraine;",311-319-330-338-349-353,330-338-349-353,"tension headaches, and MIGRAINE;","DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249585,7/11/2014 14:06:56,,1320745963,7/11/2014 14:06:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,338,353,,,347,361,HEADACHES,MIGRAINE,"tension HEADACHES,",330-338,353,MIGRAINE;,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers.",338,353,338,353,347,361,-1,RO-has_definitional_manifestation,904585,"DATA SOURCES  Studies were identified by searching MEDLINE, EMBASE/Excerpta Medica, the Cochrane Library, and International Pharmaceutical Abstracts using combinations of the terms candesartan, eprosartan, losartan, irbesartan, tasosartan, telmisartan, and valsartan and the terms headache, headache disorders, cluster headaches, tension headaches, and migraine; scanning reference lists of retrieved studies; and contacting pharmaceutical manufacturers",headaches,migraine
502249586,7/11/2014 13:30:35,,1320732948,7/11/2014 13:29:16,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,126,PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:37:03,,1320734996,7/11/2014 13:36:47,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,118-126,topical PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:39:42,,1320735832,7/11/2014 13:39:40,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,89,126,,,98,137,MYDRIASIS,PILOCARPINE,possibility of pharmacologic MYDRIASIS and correct use,60-72-75-89-99-103-111,111-115-118-126-138-146-150,use of topical PILOCARPINE testing can preclude,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:40:16,,1320736044,7/11/2014 13:40:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,118-126-138,topical PILOCARPINE testing,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:42:11,,1320736657,7/11/2014 13:41:51,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,126-118,topical PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:43:00,,1320737017,7/11/2014 13:42:31,clixsense,1.0,9343409,NLD,"","",194.120.71.114,89,126,,,98,137,MYDRIASIS,PILOCARPINE,"ophthalmoplegia, possibility of pharmacologic MYDRIASIS and correct use pilocarpine",26-60-72-75-89-99-103-111-126,26-75-89-111-115-118-126-138-146-150-177,"ophthalmoplegia, pharmacologic mydriasis use of topical PILOCARPINE testing can preclude neuroradiologic","In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 13:46:38,,1320738355,7/11/2014 13:45:50,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,89,126,,,98,137,MYDRIASIS,PILOCARPINE,"internal ophthalmoplegia, pharmacologic MYDRIASIS topical pilocarpine testing neuroradiologic and invasive diagnostic studies, atypical or complex presentations.",17-26-75-89-118-126-138-177-197-206-217-245-254-257-265-193,17-26-75-89-126-177-193-197-206-217-245-254-257-265,"internal ophthalmoplegia, pharmacologic mydriasis PILOCARPINE neuroradiologic and invasive diagnostic studies, atypical or complex presentations.","In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 14:04:45,,1320745033,7/11/2014 14:03:32,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,118-126,topical PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 14:09:02,,1320746944,7/11/2014 14:08:47,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,126-118,topical PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249586,7/11/2014 14:10:13,,1320747375,7/11/2014 14:09:39,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,89,126,,,98,137,MYDRIASIS,PILOCARPINE,pharmacologic MYDRIASIS,75-89,118-126,topical PILOCARPINE,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations.",89,126,89,126,98,137,1,RO-may_treat,908182,"In patients with internal ophthalmoplegia, awareness of the possibility of pharmacologic mydriasis and correct use of topical pilocarpine testing can preclude the necessity for neuroradiologic and invasive diagnostic studies, even in cases with atypical or complex presentations",mydriasis,pilocarpine
502249587,7/11/2014 13:27:52,,1320732080,7/11/2014 13:27:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet,17-24-29,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 13:31:53,,1320733347,7/11/2014 13:31:41,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet,17-24-29,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 13:40:34,,1320736148,7/11/2014 13:40:30,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,17,51,,,23,65,GLUTEN,CELIAC DISEASE,Adherence to a GLUTEN free diet in,2-12-15-17-24-29-34,34-37-46-51-58-66-70-75,in patients with CELIAC DISEASE can lead to,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 13:41:50,,1320736558,7/11/2014 13:41:31,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free,17-24,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 13:43:48,,1320737306,7/11/2014 13:43:21,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN celiac disease iron deficiency anemia iron deficiency.,17-51-58-96-101-112-192-197,51-58-96-101-112-142-147-192-197,"CELIAC DISEASE iron deficiency anemia iron stores, iron deficiency.","? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 13:45:06,,1320737745,7/11/2014 13:44:48,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet,17-24-29,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 14:04:58,,1320745118,7/11/2014 14:04:46,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet,17-24-29,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 14:06:34,,1320745857,7/11/2014 14:06:18,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet,17-24-29,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 14:07:29,,1320746249,7/11/2014 14:07:09,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free diet in,17-24-29-34,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249587,7/11/2014 14:10:10,,1320747368,7/11/2014 14:09:52,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,17,51,,,23,65,GLUTEN,CELIAC DISEASE,GLUTEN free,17-24,51-58,CELIAC DISEASE,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency.",17,51 58,17,51,23,65,-1,RO-has_causative_agent,903642,"? Adherence to a gluten-free diet in patients with celiac disease can lead to the correction of iron deficiency anemia and the replacement of iron stores, and it can prevent the recurrence of iron deficiency",gluten,celiac disease
502249588,7/11/2014 13:40:26,,1320736089,7/11/2014 13:40:23,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,of of,419-446,339-382-384-382,of 2 2 of,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 13:41:31,,1320736409,7/11/2014 13:40:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,CD40 monoclonal antibody plasma cell,20-25-36-389-396,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:04:50,,1320745067,7/11/2014 14:01:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,IL-6,-1,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:06:57,,1320745988,7/11/2014 14:06:03,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,IL-6,-1,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:07:54,,1320746424,7/11/2014 14:06:57,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,IL-6,-1,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:09:09,,1320746987,7/11/2014 14:09:03,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,of of,419-446,339-382-384-382,of 2 2 of,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:11:04,,1320747743,7/11/2014 14:10:34,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,IL-6,-1,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:11:46,,1320747971,7/11/2014 14:10:25,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,IL-6,-1,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:11:58,,1320748070,7/11/2014 14:10:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,plasma,389,25-36,monoclonal antibody,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249588,7/11/2014 14:14:00,,1320748834,7/11/2014 14:12:50,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,424,344,,,445,375,MONOCLONAL GAMMOPATHY,WALDENSTROM'S MACROGLOBULINEMIA,monoclonal antibody,25-36,-1,IL-6,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance.",,,424,344,445,375,-1,RO-disease_has_finding,901978,"With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM. CD40 was expressed on plasmacytoid cells in 21 of 28 plasma cell dyscrasia (PCD) bone marrow (BM) biopsies tested (10 of 14 MM, 2 of 2 Waldenstrom's macroglobulinemia [WM], 2 of 2 plasma cell leukemia [PCL], 6 of 8 monoclonal gammopathy of undetermined significance",monoclonal gammopathy,Waldenstrom's macroglobulinemia
502249589,7/11/2014 13:28:33,,1320732278,7/11/2014 13:28:15,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,147,256,PHEOCHROMOCYTOMA.,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:37:42,,1320735200,7/11/2014 13:36:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,"marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and HYPERTENSION",35-44-53-61-70-73-77-82-86-94-99-106-114-127-135-143-147-25,227-239-252-256,"parathyroid hyperplasia, and PHEOCHROMOCYTOMA.","A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:37:59,,1320735291,7/11/2014 13:37:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,147,256,PHEOCHROMOCYTOMA.,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:39:57,,1320735933,7/11/2014 13:39:54,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,"corneal nerves, and HYPERTENSION was found at",127-135-143-147-160-164-170,227-239-252-256,"parathyroid hyperplasia, and PHEOCHROMOCYTOMA.","A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:42:36,,1320736830,7/11/2014 13:42:06,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,"corneal nerves, and HYPERTENSION medullary carcinoma thyroid,",127-135-143-147-191-201-218,227-239-252-256,"parathyroid hyperplasia, and PHEOCHROMOCYTOMA.","A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:42:54,,1320736966,7/11/2014 13:42:43,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,"corneal nerves, and HYPERTENSION was found at operation",127-135-143-147-160-164-170-173,227-239-252-256,"parathyroid hyperplasia, and PHEOCHROMOCYTOMA.","A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:55:44,,1320741455,7/11/2014 13:55:28,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,corneal HYPERTENSION pheochromocytoma.,127-147-256,256,PHEOCHROMOCYTOMA.,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 13:59:18,,1320742741,7/11/2014 13:58:47,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,147,256,PHEOCHROMOCYTOMA.,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 14:07:08,,1320746069,7/11/2014 14:06:56,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,147,256,PHEOCHROMOCYTOMA.,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249589,7/11/2014 14:08:57,,1320746928,7/11/2014 14:08:46,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,147,256,,,159,272,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION at operation,147-170-173,227-239-252-256,"parathyroid hyperplasia, and PHEOCHROMOCYTOMA.","A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma.",147,256,147,256,159,272,1,RO-disease_may_have_finding,902547,"A 29-year-old man with a marfanoid habitus, peculiar mucosal neuromas of the lips and tongue, high arched palate, hyperplastic corneal nerves, and hypertension was found at operation to have medullary carcinoma of the thyroid, parathyroid hyperplasia, and pheochromocytoma",hypertension,pheochromocytoma
502249590,7/11/2014 13:41:02,,1320736272,7/11/2014 13:40:50,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,26,48,,,30,57,SKIN,PSORIASIS,primary SKIN diseases,18-26-31,48,"PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 13:43:55,,1320737332,7/11/2014 13:43:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,26,48,,,30,57,SKIN,PSORIASIS,"SKIN diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria alopecia areata",26-31-40-45-48-59-66-78-84-94-102-113-127-136,26-31-48,"skin diseases PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 13:47:22,,1320738674,7/11/2014 13:46:46,instagc,1.0,13763729,USA,"","",75.182.89.225,26,48,,,30,57,SKIN,PSORIASIS,SKIN diseases,26-31,48,"PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:03:54,,1320744682,7/11/2014 14:02:41,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,26,48,,,30,57,SKIN,PSORIASIS,SKIN diseases,26-31,48,"PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:05:36,,1320745439,7/11/2014 14:05:19,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,26,48,,,30,57,SKIN,PSORIASIS,primary SKIN diseases,18-26-31,48-59-66-78-84,"PSORIASIS, atopic dermatitis, acune vulgaris,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:08:58,,1320746924,7/11/2014 14:08:43,clixsense,1.0,9343409,NLD,"","",194.120.71.114,26,48,,,30,57,SKIN,PSORIASIS,"other hand primary SKIN diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria alopecia areata",7-13-18-26-31-40-45-48-59-66-78-84-94-102-113-127-136,31-40-45-48-59-66-78-84-94-102-113-127-136,"diseases such as PSORIASIS, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria alopecia areata","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:10:05,,1320747343,7/11/2014 14:09:54,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,26,48,,,30,57,SKIN,PSORIASIS,other hand primary SKIN diseases such as,7-13-18-26-31-40-45,31-40-45-48-59-66-78,"diseases such as PSORIASIS, atopic dermatitis, acune","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:10:18,,1320747424,7/11/2014 14:09:54,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,26,48,,,30,57,SKIN,PSORIASIS,primary SKIN diseases,18-26-31,48,"PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:10:24,,1320747460,7/11/2014 14:10:01,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,26,48,,,30,57,SKIN,PSORIASIS,SKIN diseases,26-31,48-59-66,"PSORIASIS, atopic dermatitis,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249590,7/11/2014 14:10:28,,1320747485,7/11/2014 14:10:14,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,26,48,,,30,57,SKIN,PSORIASIS,primary SKIN diseases,18-26-31,48,"PSORIASIS,","On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features.",26,48,26,48,30,57,1,RO-disease_has_primary_anatomic_site,902335,"On the other hand primary skin diseases such as psoriasis, atopic dermatitis, acune vulgaris, chronic idiopathic urticaria and alopecia areata may induce psychologic features",skin,psoriasis
502249591,7/11/2014 13:36:43,,1320734889,7/11/2014 13:36:15,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,kindled SEIZURES,67-75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 13:40:51,,1320736237,7/11/2014 13:40:34,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,inhibition of kindled SEIZURES is the result of an interaction,53-64-67-75-84-87-91-98-101-104,104-116-124-128-138-146-150-152,interaction between the MYOCLONIC SEIZURE and a subsequent,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 13:42:33,,1320736814,7/11/2014 13:41:33,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,SEIZURES,75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 13:45:22,,1320737839,7/11/2014 13:44:17,clixsense,1.0,9343409,NLD,"","",194.120.71.114,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,inhibition of kindled SEIZURES is the result myoclonic seizure subsequent,53-64-67-75-84-87-91-128-138-152,67-104-116-124-128-138-146-150-152-75,kindled seizures interaction between the MYOCLONIC SEIZURE and a subsequent,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 13:48:42,,1320739199,7/11/2014 13:48:26,instagc,1.0,13763729,USA,"","",75.182.89.225,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,SEIZURES,75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 14:00:21,,1320743125,7/11/2014 14:00:01,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,SEIZURES,75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 14:05:53,,1320745559,7/11/2014 14:05:40,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,kindled SEIZURES,67-75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 14:09:54,,1320747290,7/11/2014 14:09:29,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,kindled SEIZURES,67-75,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 14:10:16,,1320747405,7/11/2014 14:10:11,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,inhibition of kindled SEIZURES is the result,53-64-67-75-84-87-91,104-116-124-128-138-146-150-152,interaction between the MYOCLONIC SEIZURE and a subsequent,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249591,7/11/2014 14:10:40,,1320747544,7/11/2014 14:10:22,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,75,128,,,83,145,SEIZURES,MYOCLONIC SEIZURE,kindled SEIZURES,75-67,128-138,MYOCLONIC SEIZURE,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure.,75,128 138,75,128,83,145,-1,RO-has_definitional_manifestation,904708,These results suggest that the CSH-induced long-term inhibition of kindled seizures is the result of an interaction between the myoclonic seizure and a subsequent kindled seizure,seizures,myoclonic seizure
502249592,7/11/2014 13:35:01,,1320734468,7/11/2014 13:34:40,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,reoxygenation induced ARRHYTHMIAS,58-72-80,25-40-47-50-51-52-55-58,ANTIARRHYTHMIC action of L - PC on reoxygenation,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:38:42,,1320735520,7/11/2014 13:38:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,reoxygenation induced ARRHYTHMIAS,58-72-80,25-40,ANTIARRHYTHMIC action,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:39:05,,1320735648,7/11/2014 13:38:51,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,reoxygenation induced ARRHYTHMIAS,58-72-80,25,ANTIARRHYTHMIC,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:41:56,,1320736588,7/11/2014 13:41:31,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,on reoxygenation induced ARRHYTHMIAS is not correlated,55-58-72-80-92-95-99,25-58-72-80,ANTIARRHYTHMIC reoxygenation induced arrhythmias,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:43:08,,1320737040,7/11/2014 13:42:55,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,on reoxygenation induced ARRHYTHMIAS is not correlated,55-58-72-80-92-95-99,6-16-21-25-40-47-50,concluded that the ANTIARRHYTHMIC action of L,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:57:45,,1320742100,7/11/2014 13:57:24,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,80,25,ANTIARRHYTHMIC,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 13:59:50,,1320742918,7/11/2014 13:59:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,ARRHYTHMIAS,80,25,ANTIARRHYTHMIC,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 14:04:45,,1320745017,7/11/2014 14:04:31,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,reoxygenation induced ARRHYTHMIAS,58-72-80,25-40,ANTIARRHYTHMIC action,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 14:05:09,,1320745244,7/11/2014 14:04:06,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,reoxygenation induced ARRHYTHMIAS,58-80-72,25-51,ANTIARRHYTHMIC -,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249592,7/11/2014 14:06:14,,1320745707,7/11/2014 14:05:59,clixsense,1.0,9343409,NLD,"","",194.120.71.114,80,25,,,91,39,ARRHYTHMIAS,ANTIARRHYTHMIC,antiarrhythmic on reoxygenation induced ARRHYTHMIAS is not correlated electrophysiological,25-55-58-72-80-92-95-99-126,6-16-21-25-40-47-50-72-80-126-58,concluded that the ANTIARRHYTHMIC action of L reoxygenation induced arrhythmias electrophysiological,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations.,80,25,80,25,91,39,1,RO-may_prevent,907239,It is concluded that the antiarrhythmic action of L-PC on reoxygenation-induced arrhythmias is not correlated with its direct electrophysiological effects studied on normoxic preparations,arrhythmias,antiarrhythmic
502249593,7/11/2014 13:34:00,,1320734079,7/11/2014 13:33:52,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"migraine HEADACHES,",58-67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 13:35:02,,1320734467,7/11/2014 13:34:44,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"migraine HEADACHES,",58-67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 13:38:23,,1320735419,7/11/2014 13:38:12,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"HEADACHES,",67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 13:40:13,,1320736030,7/11/2014 13:39:24,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"tension headaches, migraine HEADACHES, nasosinus headaches, cluster headaches.",39-47-58-67-78-88-102-110,39-47-58-78-88-102-110-67,"tension headaches, migraine headaches, nasosinus headaches, CLUSTER HEADACHES.","Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 13:46:45,,1320738371,7/11/2014 13:46:29,instagc,1.0,13763729,USA,"","",75.182.89.225,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"HEADACHES,",67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 13:48:22,,1320739077,7/11/2014 13:48:09,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"HEADACHES,",67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 14:04:33,,1320744970,7/11/2014 14:03:55,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"migraine HEADACHES,",58-67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 14:07:49,,1320746350,7/11/2014 14:07:37,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"migraine HEADACHES,",58-67,102-110,CLUSTER HEADACHES.,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 14:08:23,,1320746664,7/11/2014 14:08:14,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"tension headaches, migraine HEADACHES, nasosinus headaches,",39-47-58-67-78-88,78-88-99-102-110,"nasosinus headaches, or CLUSTER HEADACHES.","Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249593,7/11/2014 14:08:42,,1320746806,7/11/2014 14:08:03,clixsense,1.0,9343409,NLD,"","",194.120.71.114,67,102,,,76,119,HEADACHES,CLUSTER HEADACHES,"tension headaches, migraine HEADACHES, nasosinus headaches, or cluster headaches.",39-47-58-67-78-88-99-102-110,39-47-58-78-88-99-102-110-67,"tension headaches, migraine headaches, nasosinus headaches, or CLUSTER HEADACHES.","Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches.",67,102 110,67,102,76,119,-1,RO-has_definitional_manifestation,904855,"Did the patients in these studies have tension headaches, migraine headaches, nasosinus headaches, or cluster headaches",headaches,cluster headaches
502249594,7/11/2014 13:26:58,,1320731748,7/11/2014 13:26:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384-390,"LUPUS anticoagulant,","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:32:31,,1320733568,7/11/2014 13:32:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384-390,"LUPUS anticoagulant,","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:40:13,,1320736031,7/11/2014 13:40:09,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES IgM or,313-318-321-324-341-358-362,365-369-381-384-390-405-408,"IgG cardiolipin or LUPUS anticoagulant, or false","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:40:32,,1320736127,7/11/2014 13:39:51,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384,LUPUS,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:40:42,,1320736192,7/11/2014 13:39:15,clixsense,1.0,9343409,NLD,"","",194.120.71.114,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,"Anti-Ro Gastrointestinal None Peritonitis Pancreatitis Vasculitis Protein losing enteropathy Hepatitis Ocular None Cytoid bodies Episcleritis Scleritis Hematologic Hemolytic anemia Leukopenia Lymphopenia Thrombocytopenia Anemia chronic disease Immunologic Anti - dsDNA Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES IgM or cardiolipin lupus anticoagulant, Antinuclear antibody Anti RNP Anti Ro/SSA",0-18-24-36-49-74-82-89-101-111-119-125-132-139-152-162-175-185-195-215-236-260-270-278-286-299-303-304-313-318-321-324-341-358-362-369-384-390-442-454-464-469-473-478--1,0-18-24-36-49-74-82-89-101-111-119-125-132-139-152-162-175-185-195-215-236-260-270-278-286-299-304-313-318-324-341-365-369-381-384-390-405-408-432-442-454-464-469-473-478,"Gastrointestinal None Peritonitis Pancreatitis Vasculitis Protein losing enteropathy Hepatitis Ocular None Cytoid bodies Episcleritis Scleritis Hematologic Hemolytic anemia Leukopenia Lymphopenia Thrombocytopenia Anemia chronic disease Immunologic Anti dsDNA Anti Sm Antiphospholipid antibodies IgG cardiolipin or LUPUS anticoagulant, or false syphilis) Antinuclear antibody Anti RNP Anti Ro/SSA","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:44:54,,1320737691,7/11/2014 13:44:42,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384-390,"LUPUS anticoagulant,","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:45:42,,1320737981,7/11/2014 13:45:34,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,Anti Sm or ANTIPHOSPHOLIPID ANTIBODIES IgM or,313-318-321-324-341-358-362,365-369-381-384-390-405-408,"IgG cardiolipin or LUPUS anticoagulant, or false","Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:47:41,,1320738795,7/11/2014 13:47:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384,LUPUS,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 13:51:04,,1320739954,7/11/2014 13:50:48,instagc,1.0,13763729,USA,"","",75.182.89.225,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384,LUPUS,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249594,7/11/2014 14:01:20,,1320743607,7/11/2014 14:01:00,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,324,384,,,351,389,ANTIPHOSPHOLIPID ANTIBODIES,LUPUS,ANTIPHOSPHOLIPID ANTIBODIES,324-341,384,LUPUS,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml.",324 341,384,324,384,351,389,-1,RO-has_manifestation,906360,"Gastrointestinal  None  Peritonitis Pancreatitis Vasculitis (small bowel) Protein-losing enteropathy Hepatitis Ocular  None  Cytoid bodies Episcleritis Scleritis Hematologic  Hemolytic anemia or Leukopenia (mm3) or Lymphopenia (mm3) or Thrombocytopenia (mm3)  Anemia of chronic disease Immunologic  Anti-dsDNA or Anti-Sm or Antiphospholipid antibodies (anti-IgM or IgG cardiolipin or lupus anticoagulant, or false-positive test for syphilis) Antinuclear antibody  Anti-RNP Anti-Ro/SSA Anti-La/SSB Other antibodies Modified from tvml 29tvml",Antiphospholipid antibodies,lupus
502249595,7/11/2014 13:29:29,,1320732593,7/11/2014 13:29:12,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,normal BLADDER epithelium.,150-157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 13:38:10,,1320735365,7/11/2014 13:38:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER epithelium.,157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 13:42:16,,1320736706,7/11/2014 13:41:50,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,with the normal BLADDER epithelium.,141-146-150-157-165,98-101-107-112-120-131-135-141-165,"to react with BLADDER CARCINOMA, but never with epithelium.","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 13:44:16,,1320737473,7/11/2014 13:43:49,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,"Anti Leu M1 antibody, human myelomonocytic antigen, bladder carcinoma, BLADDER epithelium.",0-5-9-12-58-64-79-112-120-157-165,5-9-12-58-64-79-98-101-107-112-120-157-165-0,"Anti Leu M1 antibody, human myelomonocytic antigen, to react with BLADDER CARCINOMA, bladder epithelium.","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 13:44:39,,1320737607,7/11/2014 13:44:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER,157,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 14:02:35,,1320744116,7/11/2014 14:02:22,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER epithelium.,157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 14:06:47,,1320745924,7/11/2014 14:06:35,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER epithelium.,157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 14:08:14,,1320746574,7/11/2014 14:08:05,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER epithelium.,157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 14:10:14,,1320747397,7/11/2014 14:10:02,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,normal BLADDER epithelium.,150-157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249595,7/11/2014 14:10:40,,1320747576,7/11/2014 14:10:19,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,157,112,,,164,129,BLADDER,BLADDER CARCINOMA,BLADDER epithelium.,157-165,112-120,"BLADDER CARCINOMA,","Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium.",157,112 120,157,112,164,129,1,RO-disease_has_primary_anatomic_site,902019,"Anti-Leu-M1 antibody, which is well known to react with a human myelomonocytic antigen, was found to react with bladder carcinoma, but never with the normal bladder epithelium",bladder,bladder carcinoma
502249596,7/11/2014 13:38:11,,1320735366,7/11/2014 13:37:48,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS in vitro,220-223-233-236,263-266-279-276,B. PERTUSSIS in vivo.,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:38:32,,1320735482,7/11/2014 13:38:14,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,263-266,B. PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:39:17,,1320735697,7/11/2014 13:39:15,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,virulence promoters of B. PERTUSSIS in vitro and,197-207-217-220-223-233-236-242,249-260-263-266-276-279,functional in B. PERTUSSIS in vivo.,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:40:16,,1320736049,7/11/2014 13:39:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,263-266,B. PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:43:12,,1320737079,7/11/2014 13:43:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,263-266,B. PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:49:38,,1320739513,7/11/2014 13:49:26,instagc,1.0,13763729,USA,"","",75.182.89.225,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,266,PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:58:17,,1320742303,7/11/2014 13:57:51,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,263-266,B. PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 13:58:19,,1320742321,7/11/2014 13:58:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,266,PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 14:00:59,,1320743456,7/11/2014 14:00:41,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS,220-223,266,PERTUSSIS,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249596,7/11/2014 14:05:12,,1320745255,7/11/2014 14:04:56,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,220,266,,,232,275,B. PERTUSSIS,PERTUSSIS,B. PERTUSSIS in vitro,220-223-233-236,263-266-276-279,B. PERTUSSIS in vivo.,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo.,220 223,266,220,266,232,275,-1,RO-has_causative_agent,903828,Here we show that a hybrid response regulator consisting of the B. pertussis derived DNA-binding output domain of BvgA(BP) combined with the B. holmesii receiver domain binds to BvgA(BP) regulated virulence promoters of B. pertussis in vitro and is functional in B. pertussis in vivo,B. pertussis,pertussis
502249597,7/11/2014 13:35:25,,1320734538,7/11/2014 13:35:03,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,131,174,,,140,179,NEPHRITIS,LUPUS,Active lupus NEPHRITIS,118-125-131,174-180,LUPUS pregnancies,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:39:43,,1320735843,7/11/2014 13:39:20,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,131,174,,,140,179,NEPHRITIS,LUPUS,Active lupus NEPHRITIS,118-125-131,174-180,LUPUS pregnancies,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:40:14,,1320736035,7/11/2014 13:39:20,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,131,174,,,140,179,NEPHRITIS,LUPUS,lupus NEPHRITIS,125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:40:35,,1320736153,7/11/2014 13:40:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,131,174,,,140,179,NEPHRITIS,LUPUS,pregnancy Active lupus NEPHRITIS,108-118-125-131,174-180,LUPUS pregnancies,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:43:13,,1320737081,7/11/2014 13:42:50,clixsense,1.0,6355877,GBR,I7,Newcastle,77.98.220.230,131,174,,,140,179,NEPHRITIS,LUPUS,Active lupus NEPHRITIS,118-125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:52:27,,1320740397,7/11/2014 13:51:50,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,131,174,,,140,179,NEPHRITIS,LUPUS,Preterm birth Moderate to severe lupus pregnancy Active lupus NEPHRITIS lupus,56-64-80-83-90-108-118-125-131-174-71,56-64-71-83-90-108-118-125-131-174,Preterm birth Moderate severe lupus pregnancy Active lupus nephritis LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 13:57:10,,1320741913,7/11/2014 13:56:12,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,131,174,,,140,179,NEPHRITIS,LUPUS,lupus NEPHRITIS,125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 14:01:11,,1320743547,7/11/2014 14:00:48,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,131,174,,,140,179,NEPHRITIS,LUPUS,Active lupus NEPHRITIS,118-125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 14:02:51,,1320744247,7/11/2014 14:01:59,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,131,174,,,140,179,NEPHRITIS,LUPUS,lupus NEPHRITIS,125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249597,7/11/2014 14:08:09,,1320746538,7/11/2014 14:07:50,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,131,174,,,140,179,NEPHRITIS,LUPUS,Active lupus NEPHRITIS,118-125-131,174,LUPUS,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity.,131,174,131,174,140,179,-1,RO-has_manifestation,906226,tvml 19tvml ; tvml 49tvml ; tvml 50tvml ; tvml 51tvml ) Preterm birth  Moderate to severe lupus activity in pregnancy Active lupus nephritis  Estimated 30% preterm birth for lupus pregnancies with low activity,nephritis,lupus
502249598,7/11/2014 13:28:20,,1320732220,7/11/2014 13:27:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS,99,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:39:24,,1320735736,7/11/2014 13:39:21,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,99,112,,,106,119,BULLETS,GUNSHOT,instruments to remove BULLETS from gunshot wounds.,77-89-92-99-107-112-120,92-99-107-112-120,remove bullets from GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:40:06,,1320735963,7/11/2014 13:39:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS from gunshot wounds.,99-107-112-120,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:42:39,,1320736837,7/11/2014 13:42:23,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS wounds.,99-120,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:46:09,,1320738164,7/11/2014 13:45:23,clixsense,1.0,9343409,NLD,"","",194.120.71.114,99,112,,,106,119,BULLETS,GUNSHOT,instruments to remove BULLETS from gunshot wounds.,77-89-92-99-107-112-120,92-99-107-112-120,remove bullets from GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:47:01,,1320738506,7/11/2014 13:46:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,99,112,,,106,119,BULLETS,GUNSHOT,instruments to remove BULLETS,77-89-92-99,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 13:56:33,,1320741709,7/11/2014 13:56:02,instagc,1.0,13763729,USA,"","",75.182.89.225,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS from gunshot wounds.,99-107-112-120,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 14:02:48,,1320744231,7/11/2014 14:02:28,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS,99,112,GUNSHOT,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 14:07:59,,1320746458,7/11/2014 14:07:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS,99,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249598,7/11/2014 14:09:41,,1320747197,7/11/2014 14:09:07,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,99,112,,,106,119,BULLETS,GUNSHOT,BULLETS from gunshot wounds.,99-107-120-112,112-120,GUNSHOT wounds.,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds.,99,112,99,112,106,119,-1,RO-has_causative_agent,903680,The Medical History Museum has the disposal of a representative selection of instruments to remove bullets from gunshot wounds,bullets,gunshot
502249599,7/11/2014 13:34:07,,1320734111,7/11/2014 13:33:38,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,primary acquired THROMBOCYTOSES.,65-73-82,0-8-20-37,Primary (ESSENTIAL) THROMBOCYTHAEMIA (PT),Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:36:24,,1320734821,7/11/2014 13:35:02,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) THROMBOCYTOSES.,0-8-20-82-37,0-8-20-37,Primary (ESSENTIAL) THROMBOCYTHAEMIA (PT),Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:39:03,,1320735632,7/11/2014 13:38:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,primary acquired THROMBOCYTOSES.,65-73-82,0-8-20,Primary (ESSENTIAL) THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:39:31,,1320735760,7/11/2014 13:39:28,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,of primary acquired THROMBOCYTOSES.,62-65-73-82,0-8-20-42-45,Primary (ESSENTIAL) THROMBOCYTHAEMIA is one,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:44:17,,1320737472,7/11/2014 13:44:06,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,of primary acquired THROMBOCYTOSES.,62-65-73-82,0-8-20-42-45-49-52-56,Primary (ESSENTIAL) THROMBOCYTHAEMIA is one of the forms,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:44:47,,1320737666,7/11/2014 13:44:39,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,THROMBOCYTOSES.,82,0-8-20,Primary (ESSENTIAL) THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:45:52,,1320738067,7/11/2014 13:45:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,THROMBOCYTOSES.,82,20,THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:47:45,,1320738803,7/11/2014 13:47:23,instagc,1.0,13763729,USA,"","",75.182.89.225,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,THROMBOCYTOSES.,82,0-8-20,Primary (ESSENTIAL) THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 13:56:08,,1320741546,7/11/2014 13:55:51,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,Primary (essential) thrombocythaemia (PT) primary acquired THROMBOCYTOSES.,0-8-20-37-65-73-82,0-8-20-37-65-73-82,Primary (ESSENTIAL) THROMBOCYTHAEMIA (PT) primary acquired thrombocytoses.,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249599,7/11/2014 14:02:39,,1320744175,7/11/2014 14:01:52,prodege,1.0,1852770,USA,TX,Abilene,76.198.102.54,82,9,,,96,36,THROMBOCYTOSES,ESSENTIAL) THROMBOCYTHAEMIA,THROMBOCYTOSES.,82,0-8-20-37,Primary (ESSENTIAL) THROMBOCYTHAEMIA (PT),Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses.,82,20,82,9,96,36,1,RO-disease_has_finding,901949,Primary (essential) thrombocythaemia (PT) is one of the forms of primary acquired thrombocytoses,thrombocytoses,essential) thrombocythaemia
502249600,7/11/2014 13:30:01,,1320732803,7/11/2014 13:29:48,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 13:37:21,,1320735098,7/11/2014 13:37:07,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 13:38:35,,1320735493,7/11/2014 13:38:24,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 13:40:22,,1320736067,7/11/2014 13:40:18,tremorgames,1,17552229,GBR,A2,Edgware,31.54.207.221,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY is a rare,0-12-24-27-29,67-69-77-80,a history of TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 13:46:33,,1320738318,7/11/2014 13:46:24,clixsense,1.0,9343409,NLD,"","",194.120.71.114,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY is a rare history trauma.,0-12-24-27-29-69-80,0-67-69-77-80-12,Purtscher's retinopathy a history of TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 13:50:12,,1320739687,7/11/2014 13:49:00,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,"PURTSCHER'S RETINOPATHY is a rare condition,",0-12-24-27-29-34,67-69-77-80,a history of TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 14:03:28,,1320744479,7/11/2014 14:03:17,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 14:03:35,,1320744540,7/11/2014 14:03:24,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 14:04:24,,1320744886,7/11/2014 14:03:19,clixsense,1,6574199,USA,TX,San Antonio,207.230.144.242,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,"PURTSCHER'S RETINOPATHY is a rare condition,",0-12-24-27-29-34,67-69-77-80,a history of TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249600,7/11/2014 14:06:10,,1320745700,7/11/2014 14:06:00,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,0,80,,,23,86,PURTSCHER'S RETINOPATHY,TRAUMA,PURTSCHER'S RETINOPATHY,0-12,80,TRAUMA.,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma.",0 12,80,0,80,23,86,1,RO-cause_of,900463,"Purtscher's retinopathy is a rare condition, seen in patients with a history of trauma",Purtscher's retinopathy,trauma
502249601,7/11/2014 13:33:38,,1320733979,7/11/2014 13:33:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,70,85,,,83,93,HERPES ZOSTER,SHINGLES,localized HERPES ZOSTER,60-70-77,84,"(SHINGLES,","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:38:12,,1320735373,7/11/2014 13:37:49,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,70,85,,,83,93,HERPES ZOSTER,SHINGLES,HERPES ZOSTER,70-77,84,"(SHINGLES,","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:42:30,,1320736794,7/11/2014 13:42:11,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"acute, localized HERPES ZOSTER (shingles, zoster)",53-60-70-77-84-95,70-77-84-95-106,"herpes zoster (SHINGLES, zoster) immunocompetent","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:43:42,,1320737270,7/11/2014 13:43:22,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"HERPES ZOSTER (shingles, zoster)",70-77-84-95,70-77-84-95,"herpes zoster (SHINGLES, zoster)","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:44:16,,1320737457,7/11/2014 13:43:56,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"of acute, localized HERPES ZOSTER",50-53-60-70-77,70-77-84-95,"herpes zoster (SHINGLES, zoster)","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:45:20,,1320737825,7/11/2014 13:45:14,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"of acute, localized HERPES ZOSTER zoster) in immunocompetent",50-53-60-70-77-95-103-106,70-77-84-95-103-106,"herpes zoster (SHINGLES, zoster) in immunocompetent","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 13:47:06,,1320738553,7/11/2014 13:46:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,70,85,,,83,93,HERPES ZOSTER,SHINGLES,HERPES ZOSTER,70-77,84,"(SHINGLES,","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 14:02:22,,1320743989,7/11/2014 14:01:59,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,70,85,,,83,93,HERPES ZOSTER,SHINGLES,HERPES ZOSTER,70-77,70-77,herpes zoster,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 14:03:51,,1320744656,7/11/2014 14:03:29,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"HERPES ZOSTER (shingles, zoster)",70-77-84-95,70-77-84-95,"herpes zoster (SHINGLES, zoster)","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249601,7/11/2014 14:09:10,,1320747007,7/11/2014 14:08:58,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,70,85,,,83,93,HERPES ZOSTER,SHINGLES,"acute, localized HERPES ZOSTER zoster)",60-70-77-95-53,70-77-84-95,"herpes zoster (SHINGLES, zoster)","27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents.",70 77,,70,85,83,93,-1,RO-has_causative_agent,903508,"27 ,   28 ,   35 ,   46  Herpes Zoster  Treatment of acute, localized herpes zoster (shingles, zoster) in immunocompetent adults and adolescents",herpes zoster,shingles
502249602,7/11/2014 13:34:13,,1320734154,7/11/2014 13:34:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:39:19,,1320735705,7/11/2014 13:39:01,prodege,1.0,27934334,GBR,F6,Romford,86.162.39.238,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:40:25,,1320736084,7/11/2014 13:40:21,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,169,143,,,173,149,PAIN,ANGINA,suggests that the PAIN is not ischemic.,151-160-165-169-174-177-181,130-134-139-143-151-160-165,"not rule out ANGINA, suggests that the","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:43:49,,1320737311,7/11/2014 13:43:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,169,143,,,173,149,PAIN,ANGINA,PAIN ischemic.,169-181,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:44:21,,1320737508,7/11/2014 13:44:06,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:45:14,,1320737799,7/11/2014 13:44:39,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:45:34,,1320737914,7/11/2014 13:45:21,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,169,143,,,173,149,PAIN,ANGINA,suggests that the PAIN is not ischemic.,151-160-165-169-174-177-181,130-134-139-143-151-160-165-169,"not rule out ANGINA, suggests that the pain","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:50:27,,1320739743,7/11/2014 13:50:03,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,169,143,,,173,149,PAIN,ANGINA,PAIN not ischemic.,169-177-181,143-169-177-181-174,"ANGINA, pain is not ischemic.","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 13:58:39,,1320742460,7/11/2014 13:58:20,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249602,7/11/2014 14:06:24,,1320745784,7/11/2014 14:06:07,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,169,143,,,173,149,PAIN,ANGINA,PAIN,169,143,"ANGINA,","A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic.",169,143,169,143,173,149,-1,RO-has_definitional_manifestation,904945,"A normal ECG taken when a patient is painfree does not rule out unstable angina; a normal ECG taken during pain, although it does not rule out angina, suggests that the pain is not ischemic",pain,angina
502249603,7/11/2014 13:32:39,,1320733612,7/11/2014 13:32:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11-18,ATOPIC diseases,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:32:39,,1320733637,7/11/2014 13:31:58,clixsense,1.0,9343409,NLD,"","",194.120.71.114,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,the prevalence of ATOPIC ECZEMA has increased substantially,57-61-72-75-82-89-93-103,0-5-11-18-27-32-35-42-46-50-61-72-75-82-57,"Like other ATOPIC diseases such as asthma and hay fever, the prevalence of atopic eczema","Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:39:45,,1320735844,7/11/2014 13:39:43,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,the prevalence of ATOPIC ECZEMA has increased substantially,57-61-72-75-82-89-93-103,0-5-11-18-27-32,Like other ATOPIC diseases such as,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:41:19,,1320736362,7/11/2014 13:41:04,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,the prevalence of ATOPIC ECZEMA has increased substantially,57-61-72-75-82-89-93-103,0-5-11-18-27-32-35,Like other ATOPIC diseases such as asthma,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:42:52,,1320736964,7/11/2014 13:42:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11-18,ATOPIC diseases,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:45:22,,1320737838,7/11/2014 13:45:01,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,atopic diseases ATOPIC ECZEMA has increased substantially,11-18-75-82-89-93-103,11-18-27-32-35-46-50,"ATOPIC diseases such as asthma hay fever,","Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:52:50,,1320740537,7/11/2014 13:52:33,instagc,1.0,13763729,USA,"","",75.182.89.225,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11-18,ATOPIC diseases,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 13:54:57,,1320741195,7/11/2014 13:54:21,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11-18,ATOPIC diseases,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 14:00:40,,1320743248,7/11/2014 14:00:22,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11,ATOPIC,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249603,7/11/2014 14:05:39,,1320745461,7/11/2014 14:05:25,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,75,11,,,88,17,ATOPIC ECZEMA,ATOPIC,ATOPIC ECZEMA,75-82,11-18,ATOPIC diseases,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown.",75 82,11,75,11,88,17,-1,RO-cause_of,900195,"Like other atopic diseases such as asthma and hay fever, the prevalence of atopic eczema has increased substantially over the last 30 years, for reasons largely unknown",atopic eczema,atopic
502249604,7/11/2014 13:40:16,,1320736050,7/11/2014 13:40:12,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,76,102,,,84,104,BLEEDING,PV,with increased gastrointestinal BLEEDING in patients with,44-49-59-76-85-88-97,85-88-97-102,in patients with PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 13:41:04,,1320736273,7/11/2014 13:40:51,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,76,102,,,84,104,BLEEDING,PV,with increased gastrointestinal BLEEDING in patients with PV.,44-49-59-76-85-88-97-102,85-88-97-102,in patients with PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 13:41:08,,1320736331,7/11/2014 13:40:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,76,102,,,84,104,BLEEDING,PV,gastrointestinal BLEEDING,59-76,102,PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 13:43:22,,1320737135,7/11/2014 13:43:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,76,102,,,84,104,BLEEDING,PV,BLEEDING,76,102,PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 13:55:27,,1320741361,7/11/2014 13:55:12,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,76,102,,,84,104,BLEEDING,PV,BLEEDING,76,102,PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 13:56:55,,1320741837,7/11/2014 13:56:36,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,76,102,,,84,104,BLEEDING,PV,High dose aspirin increased gastrointestinal BLEEDING PV.,2-7-12-49-59-76-102,2-7-49-59-76-102-12,High dose aspirin increased gastrointestinal bleeding PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 14:03:55,,1320744695,7/11/2014 14:03:38,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,76,102,,,84,104,BLEEDING,PV,gastrointestinal BLEEDING,59-76,88-97-102,patients with PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 14:04:30,,1320744955,7/11/2014 14:04:18,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,76,102,,,84,104,BLEEDING,PV,gastrointestinal BLEEDING,59-76,102,PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 14:05:04,,1320745203,7/11/2014 14:04:25,clixsense,1.0,6574199,USA,TX,San Antonio,207.230.144.242,76,102,,,84,104,BLEEDING,PV,increased gastrointestinal BLEEDING in patients with PV.,49-59-76-85-88-97-102,49-59-85-88-97-102-76,increased gastrointestinal bleeding in patients with PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249604,7/11/2014 14:05:59,,1320745596,7/11/2014 14:05:50,prodege,1.0,1889141,USA,NC,Kinston,75.110.92.24,76,102,,,84,104,BLEEDING,PV,gastrointestinal BLEEDING,59-76,102,PV.,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV.,76,102,76,102,84,104,1,RO-disease_may_have_finding,902816,? High-dose aspirin use has been associated with increased gastrointestinal bleeding in patients with PV,bleeding,PV
502249605,7/11/2014 13:31:24,,1320733215,7/11/2014 13:31:01,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"advanced MELANOMAS,",80-71,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:42:16,,1320736703,7/11/2014 13:42:05,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"nevi or advanced MELANOMAS,",63-68-71-80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:44:37,,1320737601,7/11/2014 13:44:22,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"advanced MELANOMAS,",71-80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:45:26,,1320737872,7/11/2014 13:45:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"MELANOMAS,",80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:46:22,,1320738248,7/11/2014 13:46:10,clixsense,1.0,9343409,NLD,"","",194.120.71.114,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"melanocytes, nevi or advanced MELANOMAS, though it was malignant melanoma",34-63-68-71-80-91-98-101-133-143,34-71-119-121-130-133-143-152-155-80,"melanocytes, advanced melanomas, 9 biopsies of MALIGNANT MELANOMA in situ.","EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:51:22,,1320740029,7/11/2014 13:51:05,instagc,1.0,13763729,USA,"","",75.182.89.225,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"MELANOMAS,",80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 13:59:41,,1320742888,7/11/2014 13:59:20,clixsense,1.0,26283440,GBR,C7,Coventry,86.20.175.18,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"MELANOMAS,",80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 14:04:11,,1320744801,7/11/2014 14:03:52,eup_slw,1.0,21338859,GBR,K6,Portsmouth,86.6.113.168,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"nevi or advanced MELANOMAS,",63-71-80-68,133-143-152-155,MALIGNANT MELANOMA in situ.,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 14:08:07,,1320746521,7/11/2014 14:07:51,instagc,1.0,23149109,USA,NC,Cary,24.206.38.18,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"advanced MELANOMAS,",71-80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249605,7/11/2014 14:11:16,,1320747810,7/11/2014 14:10:41,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,80,133,,,89,151,MELANOMAS,MALIGNANT MELANOMA,"MELANOMAS,",80,133-143,MALIGNANT MELANOMA,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ.",80,133 143,80,133,89,151,-1,RO-has_manifestation,906090,"EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ",melanomas,malignant melanoma
502249606,7/11/2014 13:30:34,,1320732946,7/11/2014 13:30:19,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19-28-41-50,0,SEPSIS,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:38:51,,1320735555,7/11/2014 13:38:28,prodege,1.0,9525153,CAN,ON,Toronto,174.91.127.14,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a,7-14-17-19-28-41-50-59-69-74,0-7-14-17-19-28-41-50,SEPSIS refers to a systemic inflammatory response syndrome,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:39:19,,1320735706,7/11/2014 13:39:07,clixsense,1.0,26649250,GBR,N7,Epsom,193.117.31.2,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19-28-41-50,0,SEPSIS,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:40:08,,1320735986,7/11/2014 13:39:58,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a,7-14-17-19-28-41-50-59-69-74,0-7-14-17,SEPSIS refers to a,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:40:59,,1320736265,7/11/2014 13:40:43,clixsense,1.0,9343409,NLD,"","",194.120.71.114,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,7-14-17-19-28-41-50-59-69-74-76-86,0-7-14-17-19-28-41-50-59-86-76,SEPSIS refers to a systemic inflammatory response syndrome resulting microbial infection.,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:43:21,,1320737131,7/11/2014 13:43:09,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a,7-14-17-19-28-41-50-59-69-74,0-7-14-17-41,SEPSIS refers to a response,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:46:43,,1320738365,7/11/2014 13:46:20,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,refers to a SYSTEMIC INFLAMMATORY RESPONSE SYNDROME resulting from a microbial infection.,7-14-17-19-28-41-50-59-69-74-76-86,0-76-86,SEPSIS microbial infection.,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:53:57,,1320740915,7/11/2014 13:53:38,bitcoinget,1.0,27788878,USA,IL,Itasca,67.152.129.18,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19-28-41-50,0,SEPSIS,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:54:18,,1320741002,7/11/2014 13:54:04,instagc,1.0,13763729,USA,"","",75.182.89.225,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19-28-41-50,0,SEPSIS,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
502249606,7/11/2014 13:58:39,,1320742466,7/11/2014 13:58:19,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,19,0,,,58,6,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,19-28-41-50,0,SEPSIS,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection.,19 28 41 50,0,19,0,58,6,-1,RO-cause_of,900197,Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection,systemic inflammatory response syndrome,Sepsis
